[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 763
1. Kulkarni JN, Gorasia TK, Choudhary JP, Mahajan PP: Endometrioid carcinoma of the upper urinary tract. J Cancer Res Ther; 2010 Oct-Dec;6(4):578-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herein, we report a second case of endometrioid carcinoma of the upper urinary tract presenting 17 years after hysterectomy for high grade adenocarcinoma of ovary.
  • [MeSH-major] Endometrial Neoplasms / diagnosis. Urologic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21358108.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


2. Shidham VB, Komorowski RA, Machhi JK: Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary. Diagn Pathol; 2006;1:34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Androgen receptor expression in metastatic adenocarcinoma in females favors a breast primary.
  • BACKGROUND: The differential diagnosis of metastatic mammary adenocarcinoma and adenocarcinomas from other primary sites can be challenging, particularly in tumors that are poorly differentiated and negative for Estrogen/Progesterone receptors (ER/PR).
  • This study was undertaken to evaluate the diagnostic significance of AR expression in adenocarcinoma of breast and other morphologically similar adenocarcinomas.
  • DESIGN: Formalin-fixed paraffin-embedded tissue sections of 113 primary adenocarcinoma of various sites [breast (34, all females), lung (23, M- 6, F-17), colon (9, M-2, F-7), stomach (6, M-4, F-2), liver and bile duct (11, M-5, F-6), pancreas (7, M-2, F-5), ovary (10), endometrium (7), and cervix (6)] were immunostained with monoclonal antibody for AR.
  • RESULTS: 56% (19/34) mammary carcinoma and 20% (2/10) adenocarcinoma of ovary were positive for AR.
  • CONCLUSION: Significant proportion of mammary carcinomas and some ovarian carcinomas express AR in the nuclei of more than 10% tumor cells.
  • If metastatic tumor with unknown primary in a female is AR positive, breast and ovary are the most likely primary sites.
  • Cytoplasmic immunoreactivity alone without nuclear immunoreactivity for AR was non-specific for this differential diagnosis.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 1995 Jan-Feb;45(1):8-30 [7528632.001]
  • [Cites] Hum Pathol. 1998 Dec;29(12):1428-32 [9865828.001]
  • [Cites] J Am Acad Dermatol. 1995 May;32(5 Pt 1):711-6 [7722013.001]
  • [Cites] Mod Pathol. 2000 Feb;13(2):119-22 [10697267.001]
  • [Cites] Am J Surg Pathol. 2000 Apr;24(4):579-86 [10757407.001]
  • [Cites] Am J Clin Pathol. 2002 May;117(5):745-50 [12090423.001]
  • [Cites] Acta Cytol. 2002 Jul-Aug;46(4):651-8 [12146025.001]
  • [Cites] Am J Clin Pathol. 2003 Jun;119(6):801-6 [12817426.001]
  • [Cites] J Urol. 1992 Mar;147(3 Pt 2):798-803 [1371552.001]
  • [Cites] Int J Cancer. 1992 Oct 21;52(4):581-4 [1399140.001]
  • [Cites] Am J Clin Pathol. 2003 Nov;120(5):725-31 [14608899.001]
  • [Cites] Int Rev Cytol. 1975;41:87-172 [166046.001]
  • [Cites] J Histochem Cytochem. 1991 Jul;39(7):927-36 [1865110.001]
  • [Cites] Cancer Res. 1989 Dec 15;49(24 Pt 1):7162-7 [2582456.001]
  • [Cites] J Steroid Biochem. 1987 Mar;26(3):393-7 [3495702.001]
  • [Cites] Eur J Cancer Clin Oncol. 1985 Apr;21(4):539-42 [4007019.001]
  • [Cites] J Pathol. 1993 May;170(1):31-5 [8100853.001]
  • [Cites] J Histochem Cytochem. 1994 Jun;42(6):783-8 [8189040.001]
  • [Cites] Hum Pathol. 1993 Jan;24(1):90-5 [8418017.001]
  • [Cites] Cancer. 1996 Mar 1;77(5):934-40 [8608487.001]
  • [Cites] Mod Pathol. 1995 Dec;8(9):897-901 [8751328.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1175-80 [8883401.001]
  • [Cites] Histopathology. 1996 Sep;29(3):233-40 [8884351.001]
  • [Cites] Anticancer Res. 1996 Nov-Dec;16(6B):3803-6 [9042261.001]
  • [Cites] Mod Pathol. 1997 Aug;10(8):839-45 [9267828.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1033-8 [9831198.001]
  • [Cites] Mod Pathol. 1998 Nov;11(11):1122-6 [9831211.001]
  • [Cites] Ann Surg Oncol. 1994 Nov;1(6):495-503 [7531602.001]
  • (PMID = 17020615.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1601970
  •  go-up   go-down


3. Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M: Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol; 2009 Jun;22(6):824-32
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Glypican-3 expression in clear cell adenocarcinoma of the ovary.
  • To clarify the significance of glypican-3 expression in ovarian clear cell adenocarcinoma, we evaluated glypican-3 expression by immunohistochemistry in nonneoplastic and neoplastic ovaries, and other Müllerian duct derivatives including endometrium in different menstrual phases.
  • A total of 213 cases of ovarian adenocarcinoma, including 94 clear cell adenocarcinomas, were studied.
  • All six ovarian yolk sac tumors showed diffuse immunoreactivity for glypican-3.
  • In cases of clear cell adenocarcinoma, no correlations were found between glypican-3 expression and clinicopathological factors, such as tumor stage, lymph node metastasis, peritoneal dissemination, and death rate.
  • However, glypican-3 expression was significantly associated with poor overall survival in stage III/IV clear cell adenocarcinoma cases.
  • Our results suggest that overexpression of glypican-3 may be related to the development and aggressive behavior of ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Biomarkers, Tumor / analysis. Glypicans / biosynthesis. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19329941.001).
  • [ISSN] 1530-0285
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glypicans
  •  go-up   go-down


Advertisement
4. Roque R, Pina A, Soares C, Martinho A, Messias H: [Splenic metastasis in ovary serous adenocarcinoma]. Acta Med Port; 2007 Nov-Dec;20(6):581-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Splenic metastasis in ovary serous adenocarcinoma].
  • [Transliterated title] Metástases esplénicas no adenocarcinoma seroso do ovário.
  • The primary tumours more frequently related with splenic metastasis are lung, breast, gynaecologic, specially ovary tumours, colon, rectum and melanoma.
  • Isolated secondary splenic disease is rare, but it is described, often associated to ovary cancer.
  • We report a 55 years old women with parenchymal splenic metastases of serous ovary cystadenocarcinoma in the 5th follow up year.
  • We discuss the secondary splenic involvement of ovary cancer, dissemination route, prognosis and role of splenectomy as treatment modality in this unusual recurrence site in ovary cancers.
  • [MeSH-major] Cystadenocarcinoma, Serous / secondary. Ovarian Neoplasms / pathology. Splenic Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18331703.001).
  • [ISSN] 1646-0758
  • [Journal-full-title] Acta médica portuguesa
  • [ISO-abbreviation] Acta Med Port
  • [Language] por
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


5. Dasanu CA, Herzog TJ: Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview. Medscape J Med; 2009;11(1):6
Hazardous Substances Data Bank. DIETHYLSTILBESTROL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell adenocarcinoma of the ovary associated with in utero diethylstilbestrol exposure: case report and clinical overview.
  • BACKGROUND: Clear cell adenocarcinoma of the vagina and cervix were previously shown to be tumors occurring in female offspring exposed prenatally to diethylstilbestrol.
  • This report describes the first clinical case of clear cell adenocarcinoma of the ovary linked to early diethylstilbestrol exposure in utero.
  • She underwent surgery and staging that revealed clear cell adenocarcinoma confined to the left ovary.
  • CONCLUSION: Our case is consistent with clear cell adenocarcinoma, probably related to diethylstilbestrol exposure in utero.
  • [MeSH-major] Adenocarcinoma, Clear Cell / chemically induced. Diethylstilbestrol / adverse effects. Ovarian Neoplasms / chemically induced. Prenatal Exposure Delayed Effects / chemically induced

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Causes Control. 2001 Nov;12(9):837-45 [11714112.001]
  • [Cites] Cancer. 1980 Apr 1;45(7):1615-24 [7370920.001]
  • [Cites] Biol Reprod. 1983 Apr;28(3):735-44 [6850046.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(2):85-96 [2469661.001]
  • [Cites] Epidemiology. 2008 Mar;19(2):251-7 [18223485.001]
  • [Cites] Semin Diagn Pathol. 1997 Nov;14(4):233-9 [9383823.001]
  • [Cites] Obstet Gynecol. 2005 Jan;105(1):167-73 [15625159.001]
  • [Cites] Int J Cancer. 2007 Jul 15;121(2):356-60 [17390375.001]
  • [Cites] Semin Surg Oncol. 1990;6(6):343-6 [2263810.001]
  • (PMID = 19295927.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 731DCA35BT / Diethylstilbestrol
  • [Other-IDs] NLM/ PMC2654676
  •  go-up   go-down


6. Hanousek L, Filipová J, Lísová H: [Ovarian remnant syndrome]. Ceska Gynekol; 2009 Apr;74(2):148-50
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Ovarian remnant syndrome].
  • OBJECTIVE: We report a case of the patient who 4 years after bilateral salpingo-oophorectomy had adenocarcinoma of ovary.
  • CONCLUSION: The risk of ovarian remnant after operation is complication that is frequently related to a history of endometriosis, PID and multiple pelvic surgery.
  • These complication is called ovarian remnant syndrome.
  • Also an ovarian adenocarcinoma can develop in ovarian remnant.
  • Effective therapy of ovarian remnant may usually be achieved by an operation demanding a wide approach to retroperitoneum.

  • Genetic Alliance. consumer health - Ovarian remnant syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19514663.001).
  • [ISSN] 1210-7832
  • [Journal-full-title] Ceska gynekologie
  • [ISO-abbreviation] Ceska Gynekol
  • [Language] CZE
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


7. Panda S, Patnaik A, Mishra B: Primary carcinoma of the fallopian tube--a case report. J Indian Med Assoc; 2008 Jul;106(7):460-1
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A rare case of primary adenocarcinoma of fallopian tube is reported in a 71 years postmenopausal P6L5, presented with pain abdomen for 6 months, loss of appetite and abdominal distension for 4 months and on and off serosanguineous vaginal discharge for 1 month.
  • After clinical and laboratory evaluation it was provisionally diagnosed as a case of adenocarcinoma of ovary.
  • Exploratory laparotomy was carried out and the intra-operative diagnosis was fallopian tube carcinoma with intraperitoneal metastasis--surgical stage III disease.
  • Histopathology confirmed the diagnosis.
  • The disease process is presented in advanced stage early in the course of disease even without involving the muscularis and serosa in contrast to ovarian carcinoma which has to come through the capsule.
  • [MeSH-major] Adenocarcinoma. Fallopian Tube Neoplasms. Fallopian Tubes / pathology

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18975502.001).
  • [ISSN] 0019-5847
  • [Journal-full-title] Journal of the Indian Medical Association
  • [ISO-abbreviation] J Indian Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


8. Levälampi T, Korpela M, Vuolteenaho K, Moilanen E: Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons leading to discontinuation of the treatment. Rheumatol Int; 2008 Jan;28(3):261-9
Hazardous Substances Data Bank. Etanercept .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Etanercept was discontinued due to other adverse event in two patients: in one patient due to adenocarcinoma of ovary and in one patient due to drug-related leukopenia.

  • Genetic Alliance. consumer health - Arthritis.
  • Genetic Alliance. consumer health - Rheumatoid arthritis.
  • MedlinePlus Health Information. consumer health - Rheumatoid Arthritis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846778.001).
  • [ISSN] 1437-160X
  • [Journal-full-title] Rheumatology international
  • [ISO-abbreviation] Rheumatol. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antirheumatic Agents; 0 / Immunoglobulin G; 0 / Receptors, Tumor Necrosis Factor; FYS6T7F842 / Adalimumab; OP401G7OJC / Etanercept
  •  go-up   go-down


9. Kim SS, Nam JH, Kim SM, Choi YD, Lee JH: Peritoneal melanosis associated with mucinous cystadenoma of the ovary and adenocarcinoma of the colon. Int J Gynecol Pathol; 2010 Mar;29(2):113-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peritoneal melanosis associated with mucinous cystadenoma of the ovary and adenocarcinoma of the colon.
  • In this paper, we describe a case of peritoneal melanosis associated with a mucinous cystadenoma on an ovary and adenocarcinoma in the colon of 68-year-old women.
  • A pelvic computed tomographic scan revealed a huge multicystic mass on the right ovary and a well-enhancing intraluminal mass located at the rectosigmoid junction.
  • During a surgical procedure, India-ink-colored (black) pigmentation was seen in the peritoneum, in the omentum, and on the surface of the ovary.
  • Pigment was also present in the wall of the mucinous cystadenoma of the ovary and colonic serosa.
  • [MeSH-major] Adenocarcinoma / pathology. Cystadenoma, Mucinous / pathology. Melanosis / pathology. Ovarian Neoplasms / pathology. Peritoneum / pathology. Sigmoid Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20173496.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Komiyama S, Nakamura M, Murakami I, Kuwabara Y, Kurahashi T, Tanaka K, Mikami M: A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine. Arch Gynecol Obstet; 2008 Dec;278(6):565-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A heavily pretreated patient with recurrent clear cell adenocarcinoma of the ovary in whom carcinomatous peritonitis was controlled successfully by salvage therapy with gemcitabine.
  • INTRODUCTION: Advanced clear cell adenocarcinoma of the ovary is a histologic type with an extremely poor prognosis.
  • No reports have been published concerning useful drugs for salvage chemotherapy for this type of cancer.
  • We performed salvage therapy with gemcitabine in a patient with multiple-drug- resistant, unresectable recurrent clear cell adenocarcinoma of the ovary and succeeded in stabilizing recurrent lesions and controlling carcinomatous peritonitis.
  • CASE REPORT: A 55-year-old woman was in Stage IIIc of clear cell adenocarcinoma of the ovary.
  • CONCLUSION: Gemcitabine is also useful for heavily pretreated clear cell adenocarcinoma of the ovary.
  • It is necessary to consider the use of drugs without cross resistance to platinum and taxanes in the selection of drugs for this cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Neoplasm Recurrence, Local / drug therapy. Ovarian Neoplasms / drug therapy. Peritonitis / drug therapy. Salvage Therapy / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Arch Gynecol Obstet. 2009 Feb;279(2):271. Komiyama, Shin [corrected to Komiyama, Shin-ichi]
  • (PMID = 17576588.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. Valenzuela P, Ramos P, Redondo S, Cabrera Y, Alvarez I, Ruiz A: Endometrioid adenocarcinoma of the ovary and endometriosis. Eur J Obstet Gynecol Reprod Biol; 2007 Sep;134(1):83-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma of the ovary and endometriosis.
  • OBJECTIVE: We present a retrospective analysis of 22 cases of endometrioid ovarian carcinoma, reviewed to identify endometriosis and its malignant transformation.
  • STUDY DESIGN: Twenty-two patients with endometrioid ovarian cancer were included in the review.
  • In another patient, the transition zone was abrupt and present in both ovaries.
  • In the third, a pre-menopausal woman, ovarian endometriosis with only focal endometrioid carcinoma was observed.
  • CONCLUSION: Although this association is not very frequent, patients with ovarian endometriosis and a high CA 125 serum level should be managed with special care, regardless of their pre-menopausal or post-menopausal status.
  • [MeSH-major] Adenocarcinoma, Clear Cell. Carcinoma, Endometrioid / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16844279.001).
  • [ISSN] 0301-2115
  • [Journal-full-title] European journal of obstetrics, gynecology, and reproductive biology
  • [ISO-abbreviation] Eur. J. Obstet. Gynecol. Reprod. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


12. Shimada M, Kigawa J, Ohishi Y, Yasuda M, Suzuki M, Hiura M, Nishimura R, Tabata T, Sugiyama T, Kaku T: Clinicopathological characteristics of mucinous adenocarcinoma of the ovary. Gynecol Oncol; 2009 Jun;113(3):331-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological characteristics of mucinous adenocarcinoma of the ovary.
  • OBJECTIVE: We conducted the present study to clarify the clinicopathological characteristics of mucinous adenocarcinoma.
  • METHODS: Two hundred twenty-five patients were diagnosed with mucinous adenocarcinoma at individual institutes and underwent primary treatment between 1998 and 2003.
  • Of 189 patients undergoing central pathological review, 64 patients (33.9%) were diagnosed with mucinous invasive adenocarcinoma, 45 mucinous intraepithelial carcinoma, and 42 mucinous tumor of borderline malignancy.
  • Twenty-five patients were diagnosed with other histological subtypes, including 8 endometrioid adenocarcinoma, 5 clear cell carcinoma, 3 serous adenocarcinoma, and 4 mixed type.
  • There were 13 cases of metastatic mucinous adenocarcinoma, including 7 pseudomyxoma peritonei.
  • Four hundred thirty-three patients with serous adenocarcinoma were used as controls.
  • There was no difference in the outcome between mucinous invasive adenocarcinoma and serous adenocarcinoma in I-II stage patients and III-IV stage patients with optimal operation.
  • In contrast, patients with mucinous invasive adenocarcinoma receiving suboptimal operation showed a significantly worse prognosis (survival rate: 27.8% vs. 61.5%).
  • The response rate to chemotherapy for mucinous invasive adenocarcinoma was significantly lower than for serous adenocarcinoma (12.5% vs. 67.7%).
  • CONCLUSIONS: The diagnosis of mucinous invasive adenocarcinoma was difficult.
  • Since patients with mucinous invasive adenocarcinoma had a lower response to chemotherapy, aggressive cytoreductive surgery was an effective treatment to improve the prognosis for advanced stage patients.
  • A new chemotherapeutic regimen should be established for mucinous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19275957.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Suzuki N, Yoshioka N, Uekawa A, Matsumura N, Tozawa A, Koike J, Konishi I, Kiguchi K, Ishizuka B: Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target. Int J Gynecol Cancer; 2010 Feb;20(2):212-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target.
  • OBJECTIVE: Clear cell adenocarcinoma of the ovary often shows resistance to anticancer agents.
  • It accounts for 20% of epithelial ovarian cancer in Japan versus around 5% in other countries.
  • We investigated new molecules to use when developing molecular-targeting therapy for clear cell adenocarcinoma.
  • METHODS: Reverse transcriptase polymerase chain reaction and Western blot analysis were performed to confirm the expression of POU6F1 in several kinds of cell lines derived from epithelial ovarian carcinoma.
  • Microarray analyses were performed using 2 ovarian cancer microarray data sets available on the Internet.
  • Immunohistochemical staining was also done to confirm both the expression and the localization of POU6F1 using human ovarian epithelial ovarian carcinoma tissue specimens.
  • In addition, the gene cluster located downstream of transcription factor POU6F1 was investigated to analyze its role in the proliferation of clear cell adenocarcinoma of the ovary via the lysophosphatidic acid receptor, a G protein-coupled receptor.
  • Furthermore, RNA interference studies with small interfering RNA (siRNA) were performed to assess the effect of POU6F1 on proliferation of xenograft tumors after injection of clear cell adenocarcinoma cells into nude mice.
  • RESULTS: Expression of POU6F1 at messenger RNA and protein was confirmed in cell lines derived from epithelial ovarian carcinoma.
  • The microarray analyses performed using the 2 ovarian cancer microarray data sets available on the Internet indicated that POU6F1 expression was significantly greater in clear cell adenocarcinoma.
  • Immunostaining confirmed the nuclear localization of POU6F1 in clear cell adenocarcinoma (100%).
  • POU6F1 siRNA dose-dependently suppressed the proliferation of clear cell adenocarcinoma cell lines, and a similar effect was confirmed for tumors transplanted into nude mice.
  • CONCLUSIONS: Clear cell adenocarcinoma shows little response to standard therapy.
  • The results of this study suggested that the transcription factor POU6F1 could be a new molecular target for treatment of this cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Ovarian Neoplasms / metabolism. POU Domain Factors / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20134265.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Multienzyme Complexes; 0 / POU Domain Factors; 0 / POU6F1 protein, human; 0 / RNA, Small Interfering; 0 / Receptors, Lysophosphatidic Acid; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.1 / Phosphodiesterase I; EC 3.1.4.39 / alkylglycerophosphoethanolamine phosphodiesterase; EC 3.6.1.- / Pyrophosphatases
  •  go-up   go-down


14. Rose PG, Drake R, Braly PS, Bell MC, Wenham RM, Hines JH, Alvarez-Secord A, Soltes-Rak E, Childs BH, Herzog TJ: Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube. J Clin Oncol; 2009 May 20;27(15_suppl):5546

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preliminary results of a phase II study of oxaliplatin, docetaxel, and bevacizumab as first-line therapy of advanced cancer of the ovary, peritoneum, and fallopian tube.
  • : 5546 Background: Objectives are to estimate efficacy and safety of a novel taxane/platinum chemotherapy doublet in combination with bevacizumab (B), as first-line treatment of advanced cancer of the ovary, peritoneum or fallopian tube (FT), after initial debulking surgery.
  • Tumors were mostly ovary as primary site (84%), poorly differentiated (65%), serous adenocarcinoma pathology (73%) and FIGO stage IIIC (68.2%) or IV (14.6%).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27962510.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Scheusan R, Curescu S, Stanculeanu D, Curescu P: Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer. J Clin Oncol; 2009 May 20;27(15_suppl):e16574

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-dose methotrexate and cyclophosphamide in recurrent ovarian cancer.
  • : e16574 Background: Ovarian cancer continues to be the leading cause of death secondary to gynecologic cancers among women.
  • Metronomic chemotherapy, chronic administration of chemotherapy at relatively low, minimally toxic doses on a frequent schedule with no prolonged drug-free breaks, is a potentially novel approach to the control of advanced cancer disease.
  • PURPOSE: to evaluate the efficacy and toxicity of metronomic chemotherapy using low dose methotrexate and cyclophosphamide in patients with refractory pretreated ovarian cancer.
  • METHODS: From May 2007 to July 2008, 11 patients with refractory pretreated ovarian adenocarcinoma were included.
  • CONCLUSIONS: Metronomic metotrexate-cyclophosphamide is minimally toxic and effective in heavily pretreated recurrent ovarian cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961511.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Miyai K, Yamamoto S, Aida S, Shimazaki H, Takano M, Kudoh K, Furuya K, Tamai S, Matsubara O: Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary. Int J Gynecol Pathol; 2010 Jul;29(4):321-7
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Massive intra-abdominal undifferentiated carcinoma derived from an endometrioid adenocarcinoma in a "normal-sized" ovary.
  • We report a case of massive intra-abdominal undifferentiated carcinoma derived from a tiny well-differentiated endometrioid adenocarcinoma of the ovary.
  • Both ovaries were apparently normal in size, but a cut section of the right ovary revealed a 2-cm solid and cystic tumor showing focal rupture to the peritoneal surface.
  • The right ovarian tumor was a histologically well-differentiated endometrioid adenocarcinoma.
  • Both the intra-abdominal undifferentiated tumor and the ovarian adenocarcinoma cells were immunohistochemically positive for keratin AE1/3, Ber-EP4, and CD10.
  • Epithelial membrane antigen was positive only in the ovarian adenocarcinoma component, and vimentin was diffusely positive only in the intra-abdominal undifferentiated tumor component.
  • Allelotype analysis using 24 polymorphic markers located on 12 chromosomal arms showed that the intra-abdominal undifferentiated carcinoma and ovarian adenocarcinoma components had a high concordance rate (88%) of allelic patterns including identical allelic loss patterns at 7 chromosomal loci, suggesting a common genetic lineage.
  • These data suggest that ovarian endometrioid adenocarcinoma, even when small in size, can give rise to a massive undifferentiated carcinoma filling the peritoneal cavity.
  • [MeSH-major] Carcinoma, Endometrioid / secondary. Ovarian Neoplasms / pathology. Peritoneal Neoplasms / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20567143.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / DNA, Neoplasm; 0 / KRTAP1-3 protein, human; 0 / Keratins, Hair-Specific; 0 / Mucin-1; 0 / S100 Calcium Binding Protein G; 0 / Vimentin; 0 / human epithelial antigen-125; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


17. Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC: PTEN expression in clear cell adenocarcinoma of the ovary. Gynecol Oncol; 2006 Apr;101(1):71-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN expression in clear cell adenocarcinoma of the ovary.
  • OBJECTIVES: In this study, we analyzed the PTEN expression in a large collection of clear cell adenocarcinomas of the ovary.
  • Cyclin D1 expression and loss of p27 expression were detected in 16/40 (40.0%) and 14/40 (35.0%) clear cell adenocarcinoma cases.
  • CONCLUSIONS: Loss of PTEN expression is relatively common and both cyclin D1 and p27 expressions are not related with PTEN inactivation in clear cell adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Ovarian Neoplasms / metabolism. PTEN Phosphohydrolase / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16290000.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 136601-57-5 / Cyclin D1; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


18. Yoshioka N, Suzuki N, Uekawa A, Kiguchi K, Ishizuka B: POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary. Hum Cell; 2009 Nov;22(4):94-100
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary.
  • Clear cell adenocarcinoma of the ovary often shows resistance to anticancer agents.
  • We investigated new molecules to use when developing molecular-targeting therapy for clear cell adenocarcinoma of the ovary.
  • RMG-I cells without invasive potential and RMG-V cells with invasive potential (derived from clear cell adenocarcinoma of the ovary) were subjected to complementary deoxyribonucleic acid microarray analysis.
  • The results showed suppression of RMG-V cell infiltration by siRNA, but proliferation of the cancer cells was also suppressed.
  • These findings suggested that POU6F1 might be a transcription factor involved in the proliferation of ovarian cancer cells.
  • Clear cell adenocarcinoma of the ovary shows little response to standard therapy.
  • The results of the present study suggest that the transcription factor POU6F1 could be a new molecular target for treatment of this cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Cell Proliferation. Ovarian Neoplasms / pathology. POU Domain Factors / physiology. Transcription Factors / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19874398.001).
  • [ISSN] 1749-0774
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Caveolin 1; 0 / POU Domain Factors; 0 / POU6F1 protein, human; 0 / Transcription Factors
  •  go-up   go-down


19. Nomura H, Tamada Y, Miyagi T, Suzuki A, Taira M, Suzuki N, Susumu N, Irimura T, Aoki D: Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification. Oncol Res; 2006;16(6):289-97
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
  • Cell surface carbohydrate expression strongly influences the biological characteristics of cancer cells.
  • This study aimed to investigate sialidase expression of ovarian cancer cells and to evaluate the relationship between plasma membrane-associated sialidase (NEU3) expression and various clinicopathological factors in ovarian clear cell adenocarcinoma patients.
  • In 18 cell lines derived from human ovarian cancers (including clear cell, mucinous, and serous adenocarcinoma), sialidase mRNA expression was evaluated by RT-PCR.
  • Interestingly, NEU3 expression was detected in all clear cell adenocarcinoma cell lines.
  • In 71 patients with ovarian clear cell adenocarcinoma, treated at Keio University Hospital from February 1983 to February 2002, NEU3 expression was examined by immunohistochemical staining of surgical specimens and clinicopathological factors were reviewed.
  • This is the first report to show that NEU3 is expressed in most of ovarian clear cell adenocarcinoma.
  • And our results show that NEU3 expression is correlated with T factor (pTNM classification) in ovarian clear cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / enzymology. Adenocarcinoma, Clear Cell / pathology. Biomarkers, Tumor / metabolism. Neuraminidase / metabolism. Ovarian Neoplasms / enzymology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17476974.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 3.2.1.18 / NEU1 protein, human; EC 3.2.1.18 / NEU2 protein, human; EC 3.2.1.18 / NEU4 protein, human; EC 3.2.1.18 / Neu3 protein, human; EC 3.2.1.18 / Neuraminidase
  •  go-up   go-down


20. Miyake Y, Kato T, Oshima S, Iijima S, Kurokawa E, Okamoto Y, Kumazawa K, Chin R, Amemiya K, Adachi K, Kikkawa N: [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary]. Gan To Kagaku Ryoho; 2007 Dec;34(13):2317-9
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of metastatic rectal cancer from serous adenocarcinoma of the ovary].
  • Under diagnosis of a primary rectal cancer with peritonitis, an ileostomy was scheduled.
  • Since peritoneal dissemination was found, histologically she was diagnosed as metastatic rectal cancer from serous adenocarcinoma of the ovary.
  • No viable cancer tissue could be found.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology. Rectal Neoplasms / secondary

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18079639.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Phytogenic; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


21. Petersen M, Meyer F, Kalinski T, Bischoff J, Bohr UR, Lippert H: [Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma]. Dtsch Med Wochenschr; 2009 Jan;134(1-2):19-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Rare neuroendocrine carcinoma of the gall bladder. Coincidental occurrence of an endometrioid ovarian adenocarcinoma].
  • [Transliterated title] Seltenes neuroendokrines Karzinom der Gallenblase. Abgrenzung zur metachronen Koinzidenz mit einem endometrioiden Adenokarzinom des Ovars.
  • INVESTIGATIONS: Comparative immunochemistry, done to exclude metastatic growth of the previously demonstrated endometrioid ovarian carcinoma, was (1) negative for CK7 and CA125, positive for CK20, chromogranin A and synaptophysin (gall bladder and lymph node metastasis);.
  • (2) positive for CK7 and CA125, negative for CK20, chromogranin A and synaptophysin (ovary).
  • DIAGNOSIS: The tumor lesion within the gall bladder and lymph node was classified as a neuroendocrine carcinoma, not a metastasis of the ovarian carcinoma.
  • But for eight years there has been no recurrence of the endometrioid adenocarcinoma of the left ovary.
  • This is the first case, according to the available literature, of an endometrioid adenocarcinoma of the ovary concomitant with a neuroendocrine carcinoma of the gall bladder.
  • [MeSH-major] Carcinoma, Endometrioid / diagnosis. Carcinoma, Neuroendocrine / diagnosis. Gallbladder Neoplasms / diagnosis. Neoplasms, Second Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Dtsch Med Wochenschr. 2019 Sep;134(39):1915
  • (PMID = 19090447.001).
  • [ISSN] 1439-4413
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


22. Sparks DA, Chase DM, Forsyth M, Bogen G, Arnott J: Late presentation of a mucinous ovarian adenocarcinoma which was initially diagnosed as a primary pancreatic carcinoma: a case report and review of the literature. J Med Case Rep; 2010;4:90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Late presentation of a mucinous ovarian adenocarcinoma which was initially diagnosed as a primary pancreatic carcinoma: a case report and review of the literature.
  • INTRODUCTION: Adenocarcinoma of the ovary is an aggressive neoplasm which often metastasizes to the lung or liver.
  • Metastases rarely occur to the pancreas, but a tissue diagnosis is required to confirm this event.
  • CASE PRESENTATION: We report the case of a 51-year-old Caucasian woman with ovarian mucinous adenocarcinoma with metastasis to the head of the pancreas that was originally misdiagnosed as a pancreatic primary tumor.
  • CONCLUSION: Mucinous ovarian adenocarcinomas rarely metastasize to the pancreas.
  • New pancreatic lesions should be investigated through tissue biopsy and tumor markers, while keeping an open-minded differential diagnosis to avoid a misdiagnosis or a delay in treatment.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1989 Apr;168(4):345-7 [2928909.001]
  • [Cites] Hum Pathol. 1988 Jan;19(1):57-63 [3335391.001]
  • [Cites] Arch Gynecol Obstet. 2005 Jun;272(1):31-4 [15480722.001]
  • [Cites] Am Surg. 2002 Apr;68(4):337-40; discussion 340-1 [11952243.001]
  • [Cites] Am J Gastroenterol. 1996 Nov;91(11):2414-7 [8931428.001]
  • (PMID = 20298585.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2851597
  •  go-up   go-down


23. Kitajima K, Kaji Y, Kuwata Y, Imanaka K, Sugihara R, Sugimura K: Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary. Radiat Med; 2007 Aug 1;25(7):346-54
Hazardous Substances Data Bank. GADOPENTETATE DIMEGLUMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance imaging findings of endometrioid adenocarcinoma of the ovary.
  • PURPOSE: We assessed magnetic resonance imaging (MRI) features and clinical characteristics of ovarian endometrioid adenocarcinoma.
  • MATERIALS AND METHODS: A total of 31 patients with 39 surgically proven ovarian endometrioid adenocarcinomas were analyzed retrospectively.
  • CONCLUSION: MRI of ovarian endometrioid adenocarcinomas revealed two types: a solid type and a cystic type.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17705005.001).
  • [ISSN] 0288-2043
  • [Journal-full-title] Radiation medicine
  • [ISO-abbreviation] Radiat Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media; K2I13DR72L / Gadolinium DTPA
  •  go-up   go-down


24. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R: WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer; 2005 Nov 1;104(9):1924-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma.
  • BACKGROUND: Ovarian clear cell adenocarcinoma is associated with one of the poorest prognoses among human epithelial ovarian cancers.
  • The authors hypothesized that Wilms tumor suppressor 1 gene (WT1) sense and antisense (WT1-AS) expression and their promoter methylation status could characterize ovarian clear cell adenocarcinoma from ovarian serous adenocarcinoma.
  • METHODS: To test this hypothesis, ovarian cancer cell lines and 42 cancer tissues (17 clear cell and 25 serous adenocarcinoma) were analyzed for expression and methylation of WT1 and WT1-AS genes.
  • RESULTS: These experiments demonstrated that all serous adenocarcinoma tissues expressed both WT1 and WT1-AS genes, although expression of these genes was lacking in clear cell adenocarcinoma.
  • The WT1 and WT1-AS promoter were significantly methylated in clear cell adenocarcinoma (88.2% and 88.2%, respectively) compared with serous adenocarcinoma (24.0% and 20.0%, respectively).
  • Also in agreement with these data, WT1 and WT1-AS negative ovarian cancer cell lines reexpressed these genes after treatment with the demethylating agent, 5-aza-2'-deoxycytidine.
  • CONCLUSIONS: The current study shows that CpG hypermethylation is an important mechanism of WT1 and WT1-AS gene inactivation in ovarian clear cell adenocarcinoma.
  • This is the first report that has demonstrated differential expression and methylation of WT1-AS in ovarian clear cell and serous adenocarcinomas.
  • This study presents new molecular characterizations between these two types of adenocarcinoma and may provide insight as to why clear cell adenocarcinoma has a poorer prognosis than serous adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Cystadenocarcinoma, Serous / genetics. DNA Methylation. DNA, Antisense / metabolism. Ovarian Neoplasms / genetics. WT1 Proteins / genetics

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16134181.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / R01AG21418; United States / NCI NIH HHS / CA / R01CA101844; United States / NIDDK NIH HHS / DK / T32DK07790
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Antisense; 0 / WT1 Proteins
  •  go-up   go-down


25. Mizuno M, Kikkawa F, Shibata K, Kajiyama H, Ino K, Kawai M, Nagasaka T, Nomura S: Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary. J Surg Oncol; 2006 Aug 1;94(2):138-43
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term follow-up and prognostic factor analysis in clear cell adenocarcinoma of the ovary.
  • BACKGROUND AND OBJECTIVES: There were a few reports of a large number of patients with clear cell adenocarcinoma (CCA) of the ovary because of the low incidence of CCA.
  • Thus, substaging is quite important for comparison of prognoses between histologies, and CCA showed poorer prognoses than serous adenocarcinoma in stages IIIb and IIIc.
  • [MeSH-major] Adenocarcinoma, Clear Cell / mortality. Ovarian Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2006 Wiley-Liss, Inc.
  • (PMID = 16847906.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Tsuda H, Ito K, Yaegashi N, Hirasawa A, Sudo T, Kita T, Terai Y, Kigawa J, Sugiyama T, Aoki D: Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary. Int J Gynecol Cancer; 2010 Jul;20(5):794-7
Hazardous Substances Data Bank. PLATINUM COMPOUNDS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between ABCF2 expression and response to chemotherapy or prognosis in clear cell adenocarcinoma of the ovary.
  • OBJECTIVES: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphate-binding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary.
  • CONCLUSIONS: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.
  • [MeSH-major] ATP-Binding Cassette Transporters / biosynthesis. Adenocarcinoma, Clear Cell / drug therapy. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20973270.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABCF2 protein, human; 0 / Antineoplastic Agents; 0 / Platinum Compounds
  •  go-up   go-down


27. Nagai Y, Inamine M, Hirakawa M, Kamiyama K, Ogawa K, Toita T, Murayama S, Aoki Y: Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol; 2007 Dec;107(3):469-73
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary.
  • OBJECTIVES: The aim of this study was to clarify the efficacy of postoperative whole abdominal radiotherapy (WAR) for ovarian clear cell adenocarcinoma (OCCA).
  • [MeSH-major] Adenocarcinoma, Clear Cell / radiotherapy. Ovarian Neoplasms / radiotherapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765295.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CISCA protocol
  •  go-up   go-down


28. Nakazato T, Kanuma T, Tamura T, Faried LS, Aoki H, Minegishi T: Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer. Int J Gynecol Cancer; 2007 Mar-Apr;17(2):426-32
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sperm protein 17 influences the tissue-specific malignancy of clear cell adenocarcinoma in human epithelial ovarian cancer.
  • Clear cell adenocarcinoma of the ovary has a poor prognosis due to chemoresistance and early metastasis to the lymph nodes.
  • It also can result in endometriosis and is the second most frequent type of ovarian cancer in Japan.
  • Serous adenocarcinoma of the ovary is another common epithelial cancer tissue subtype in Japan, and it is highly sensitive to chemotherapy.
  • In the current study, we examined the differential expression of genes in these types of ovarian cancer and tried to analyze their functions, especially as they relate to chemoresistance.
  • We used differential display to compare clear cell carcinoma and serous adenocarcinoma of the ovary.
  • Because the function of the SP17 gene in ovarian cancer is not known, we examined the effect of small interfering RNA targeting the SP17 gene on the chemoresistance and proliferation of ES-2 ovarian cancer cells to paclitaxel, currently the most effective treatment for ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenocarcinoma, Clear Cell / pathology. Antigens, Surface / genetics. Carrier Proteins / genetics. Drug Resistance, Neoplasm / genetics. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian cancer.
  • Genetic Alliance. consumer health - Ovarian epithelial cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17309563.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Surface; 0 / Carrier Proteins; 0 / RNA, Small Interfering; 0 / SPA17 protein, human
  •  go-up   go-down


29. Geisler JP, Buller E, Manahan KJ: Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary. Eur J Gynaecol Oncol; 2008;29(2):126-8
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor alpha and beta expression in a case matched series of serous and endometrioid adenocarcinomas of the ovary.
  • OBJECTIVE: The purpose of this study was to analyze estrogen receptor alpha and beta (ERalpha, ERbeta) expression in a stage and grade matched cohort of patients with serous and endometrioid adenocarcinoma of the ovary.
  • METHODS: Forty-two patients from 1991 to the present were found to have the diagnosis of endometrioid adenocarcinoma of the ovary and have tissue available for analysis.
  • These were stage and grade matched with ten patients having serous adenocarcinoma of the ovary during the same time period.
  • CONCLUSIONS: ERalpha expression, but not ERbeta expression, is significantly more common in endometrioid than serous adenocarcinomas of the ovary when controlled for stage and grade.
  • [MeSH-major] Carcinoma, Endometrioid / metabolism. Cystadenocarcinoma, Serous / metabolism. Estrogen Receptor alpha / genetics. Estrogen Receptor beta / genetics. Ovarian Neoplasms / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459544.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA 79445-01A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Estrogen Receptor alpha; 0 / Estrogen Receptor beta; 0 / RNA, Messenger
  •  go-up   go-down


30. Soto Delgado M, Pedrero Márquez G, Varo Solís C, Rodríguez-Rubio Cortadellas FO, Sánchez Bernal C, González Moreno D: [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma]. Actas Urol Esp; 2006 Feb;30(2):222-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mucinous adenocarcinoma of the urachus and peritoneal pseudomyxoma].
  • [Transliterated title] Adenocarcinoma mucinoso de uraco y pseudomixoma peritoneal.
  • The adenocarcinoma of the urachus is very rare tumor, with an incidence of 1/5.000.000 inhabitants, represents less than 0.001 of all types of bladder cancer.
  • Usually is associated with benign o malignant mucinous tumor of the appendix or ovary.
  • In this paper, we present a case of peritoneal pseudomixoma caused by a mucinous adenocarcinoma of the urachus.
  • [MeSH-major] Adenocarcinoma, Mucinous / complications. Pseudomyxoma Peritonei / etiology. Urachus

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16700214.001).
  • [ISSN] 0210-4806
  • [Journal-full-title] Actas urologicas españolas
  • [ISO-abbreviation] Actas Urol Esp
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


31. Shimizudani N, Senba S, Komiyama M, Hatao H, Ito M, Kioi K, Sudo A, Kishi K, Yagyu H, Oh-ishi S, Nakamura H, Matsuoka T: [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma]. Nihon Kokyuki Gakkai Zasshi; 2005 Apr;43(4):236-40
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pseudo-meigs syndrome due to ovarian clear cell adenocarcinoma].
  • Computed tomography (CT) of the abdomen showed a huge mass of the right ovary with a small amount of ascites, suggesting a diagnosis of Meigs syndrome.
  • The ovarian mass and the neighboring organs, including the uterus and the greater omentum, were surgically removed, and then both the bilateral pleural effusion and ascites disappeared after the surgery.
  • The histopathological examination revealed that the mass was clear cell adenocarcinoma of the ovary (stage IIc), indicating that the disease was pseudo-Meigs Syndrome.
  • This is the second report of pseudo-Meigs Syndrome caused by clear cell adenocarcinoma of the ovary in Japan.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Adenocarcinoma, Clear Cell / surgery. Meigs Syndrome / etiology. Ovarian Neoplasms / complications. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966371.001).
  • [ISSN] 1343-3490
  • [Journal-full-title] Nihon Kokyūki Gakkai zasshi = the journal of the Japanese Respiratory Society
  • [ISO-abbreviation] Nihon Kokyuki Gakkai Zasshi
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Takakura S, Takano M, Takahashi F, Saito T, Aoki D, Inaba N, Noda K, Sugiyama T, Ochiai K, Japanese Gynecologic Oncology Group: Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer; 2010 Feb;20(2):240-7
Hazardous Substances Data Bank. CARBOPLATIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study.
  • INTRODUCTION: Paclitaxel plus carboplatin (TC) is generally considered to be the "gold standard" regimen for treatment of epithelial ovarian carcinomas.
  • Little data are available, however, on the use of this regimen in patients with clear cell adenocarcinoma of the ovary (CCC).
  • [MeSH-major] Adenocarcinoma, Clear Cell / drug therapy. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20169667.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 7673326042 / irinotecan; BG3F62OND5 / Carboplatin; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


33. Rekhi B, George S, Madur B, Chinoy RF, Dikshit R, Maheshwari A: Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa. Diagn Pathol; 2008;3:39
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological features and the value of differential Cytokeratin 7 and 20 expression in resolving diagnostic dilemmas of ovarian involvement by colorectal adenocarcinoma and vice-versa.
  • The distinction between metastasis from a colorectal adenocarcinoma into the ovary and an ovarian adenocarcinoma is vital, but challenging at times, due to overlapping morphological features.
  • Similarly, a distinction between an ovarian metastasis into the colorectum and a colorectal adenocarcinoma, although rare; is important and can be daunting.
  • We report an analysis of 20 cases of ovarian involvement by metastatic colorectal adenocarcinomas and colorectal involvement by metastatic ovarian adenocarcinomas, including the value of differential expression of cytokeratins 7 & 20 by immunohistochemistry (IHC), in these cases.
  • Nine cases (45%) were identified as colorectal adenocarcinomas metastatic to the ovary.
  • Other 11 cases (55%) were ovarian adenocarcinomas, metastatic to the colorectum.
  • These showed metachronous presentations, with the ovarian tumor preceding the colorectal tumor deposits.
  • On IHC, CK7 and CA 125 were positive in all 6 of 11 such cases, whereas CK 20 was negative in all these cases.In cases of complex presentations like an ovarian involvement by a metastatic colorectal adenocarcinoma and vice-versa, certain clinicopathological features are useful.
  • CK20 positivity and CK7 negativity is associated with a colorectal adenocarcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Am J Clin Pathol. 2002 Jun;117(6):944-51 [12047147.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):97-101 [16278010.001]
  • [Cites] Am J Surg Pathol. 2006 Feb;30(2):177-84 [16434891.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Dis Colon Rectum. 1998 Oct;41(10):1312-4; discussion 1314-5 [9788396.001]
  • [Cites] Hum Pathol. 1998 May;29(5):491-7 [9596273.001]
  • [Cites] Jpn J Clin Oncol. 1997 Jun;27(3):193-6 [9255277.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):368-81 [8996164.001]
  • [Cites] Gynecol Oncol. 1995 Nov;59(2):200-6 [7590473.001]
  • [Cites] Am J Pathol. 1992 Feb;140(2):427-47 [1371204.001]
  • [Cites] Am J Clin Pathol. 1992 Jun;97(6):745-7 [1595593.001]
  • [Cites] Cancer. 1989 Oct 1;64(7):1508-13 [2776109.001]
  • [Cites] Am J Surg Pathol. 1987 Feb;11(2):114-21 [3812871.001]
  • [Cites] Am J Pathol. 1990 Mar;136(3):641-55 [1690512.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):850-3 [15350388.001]
  • [Cites] Hum Pathol. 2002 Nov;33(11):1078-85 [12454811.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):3-32 [16512597.001]
  • (PMID = 18801162.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2556647
  •  go-up   go-down


34. Yamamoto S, Tsuda H, Takano M, Hase K, Tamai S, Matsubara O: Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway. J Pathol; 2008 Sep;216(1):103-10
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear-cell adenofibroma can be a clonal precursor for clear-cell adenocarcinoma of the ovary: a possible alternative ovarian clear-cell carcinogenic pathway.
  • Several studies have reported that ovarian clear-cell adenocarcinoma can be derived from endometriosis.
  • Although the clear-cell adenofibroma (CCAF), a major form of benign and borderline ovarian clear-cell tumour, has been suggested as another precursor for clear-cell adenocarcinoma (CCA), there is no supportive genetic evidence for this presumption.
  • To examine the genetic linkage between CCAF and CCA of the ovary, we conducted allelotype analysis for both CCAF and adjacent CCA components in 14 cases of CCA associated with benign CCAF and/or borderline CCAF.
  • For all informative loci, the frequency of LOH in adenocarcinoma was 49% (54/110 loci), and was significantly higher than those in the components of benign CCAF (22%, 20/92 loci) and borderline CCAF (30%, 25/83 loci) (chi(2) test; p<0.05, respectively).
  • The concordance rate in allelic patterns at all informative loci was 74% between benign CCAF and adenocarcinoma components, 81% between borderline CCAF and adenocarcinoma components, and 95% between benign CCAF and borderline CCAF components.
  • Furthermore, between CCAF and adenocarcinoma components, an identical LOH pattern, involving the same alleles, was found in 13 (93%) of 14 cases at one or more chromosomal loci, and estimation of probability indicated that these events were very unlikely to have occurred by chance.
  • Among the markers examined, LOHs on 5q, 10q and 22q were frequent in both CCAF and adenocarcinoma components, whereas LOHs on 1p and 13q were rare in CCAF components but frequent in adenocarcinoma components.
  • These findings suggest that CCAF can be a clonal precursor for ovarian clear-cell adenocarcinoma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / genetics. Adenofibroma / genetics. Biomarkers, Tumor / analysis. Ovarian Neoplasms / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18600856.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Ghataorhe P, Kurian AW, Pickart A, Trapane P, Norton JA, Kingham K, Ford JM: A carrier of both MEN1 and BRCA2 mutations: case report and review of the literature. Cancer Genet Cytogenet; 2007 Dec;179(2):89-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • High-penetrance autosomal dominant cancer susceptibility genes such as BRCA2 and MEN1 result in specific patterns of cancers in individuals who inherit germline mutations.
  • Their incidence in the population is relatively low, however, and it is highly unusual to identify individuals with two or more inherited cancer gene mutations.
  • We describe a family with multiple cases of MEN1-associated cancers as well as pancreatic adenocarcinoma, ovarian cancer, and male breast cancer, in which we identified germline mutations in both MEN1 and BRCA2.
  • [MeSH-minor] Adenocarcinoma / genetics. Adult. Family Health. Female. Heterozygote. Humans. Multiple Endocrine Neoplasia / genetics. Pedigree

  • MedlinePlus Health Information. consumer health - Hyperthyroidism.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18036394.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MEN1 protein, human; 0 / Proto-Oncogene Proteins
  • [Number-of-references] 27
  •  go-up   go-down


36. Sato S, Itamochi H, Kigawa J, Oishi T, Shimada M, Sato S, Naniwa J, Uegaki K, Nonaka M, Terakawa N: Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy. Cancer Sci; 2009 Mar;100(3):546-51
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy of oxaliplatin and 5-fluorouracil may be an effective regimen for mucinous adenocarcinoma of the ovary: a potential treatment strategy.
  • Resistance of ovarian mucinous adenocarcinoma to standard chemotherapy with paclitaxel and carboplatin is associated with poor prognosis, and an effective treatment is needed.
  • The present study aimed to identify an effective chemotherapy for ovarian mucinous adenocarcinoma.
  • Five human ovarian mucinous adenocarcinoma cell lines (MN-1, OMC-1, RMUG-L, RMUG-S, TU-OM-1) were used in this study.
  • The combination of oxaliplatin and 5-fluorouracil significantly prolonged survival in a ovarian mucinous adenocarcinoma xenograft model of nude mice.
  • Exposure to 5-fluorouracil down-regulated cross-complementation group 1 expression in ovarian mucinous adenocarcinoma cells.
  • We conclude that combination chemotherapy consisting of oxaliplatin and 5-fluorouracil was an effective treatment for ovarian mucinous adenocarcinoma and may be a pivotal candidate for a novel treatment strategy.
  • [MeSH-major] Adenocarcinoma, Mucinous / drug therapy. Antineoplastic Combined Chemotherapy Protocols / pharmacology. Fluorouracil / administration & dosage. Organoplatinum Compounds / administration & dosage. Ovarian Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19154404.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; U3P01618RT / Fluorouracil
  •  go-up   go-down


37. Sciallis AP, Aubry MC, Bell DA: Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case. Int J Gynecol Pathol; 2009 Sep;28(5):447-52
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ciliated adenocarcinoma of the ovary with evidence of serous differentiation: report of a case.
  • A patient with bilateral ovarian adenocarcinomas composed predominantly of ciliated cells incidentally found at autopsy is reported.
  • The tumor was confined to the ovaries without evidence of metastatic spread.
  • [MeSH-major] Adenocarcinoma / pathology. Cilia / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19696614.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Tamada Y, Takeuchi H, Suzuki N, Susumu N, Aoki D, Irimura T: Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary. Cancer Sci; 2007 Oct;98(10):1586-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
  • A monoclonal antibody (mAb) MY.1E12 was applied to detect MUC1 with sialylated glycans in a total of 55 formalin-fixed, paraffin-embedded surgical specimens of ovarian clear cell adenocarcinomas.
  • To examine the role of MUC1 in ovarian clear cell carcinomas, two cDNA encoding MUC1 were transfected into ES-2 ovarian clear cell carcinoma cells.
  • The results indicate that MUC1 expressed on ovarian clear cell carcinoma cells is causally involved in the malignant behavior.
  • [MeSH-major] Adenocarcinoma, Clear Cell / immunology. Antibodies, Monoclonal. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Mucin-1 / immunology. Ovarian Neoplasms / immunology. Sialic Acids / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17711507.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Mucin-1; 0 / Sialic Acids; P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


39. Moore KN, Moxley KM, Fader AN, Axtell AE, Rocconi RP, Abaid LN, Cass IA, Rose PG, Leath CA 3rd, Rutledge T, Blankenship D, Gold MA: Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary. Gynecol Oncol; 2007 Dec;107(3):398-403
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
  • We sought to compare survival trends between PCFT and ovarian carcinoma (OC) patients (pts) in a matched, case-control comparison.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Cystadenocarcinoma, Serous / therapy. Fallopian Tube Neoplasms / pathology. Fallopian Tube Neoplasms / therapy. Ovarian Neoplasms / pathology. Ovarian Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Gynecol Oncol. 2007 Dec;107(3):386-7 [18053873.001]
  • (PMID = 17997146.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Organoplatinum Compounds; 0 / Taxoids; 1605-68-1 / taxane
  •  go-up   go-down


40. Pervatikar SK, Rao R, Dinesh US: Ossifying luteinized thecoma of the ovary with endometrial adenocarcinoma. Indian J Pathol Microbiol; 2009 Apr-Jun;52(2):222-4
MedlinePlus Health Information. consumer health - Uterine Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ossifying luteinized thecoma of the ovary with endometrial adenocarcinoma.
  • Luteinized thecomas are one of the sex cord stromal tumors of the ovary rarely undergoing ossification.
  • Endometrial curettage performed showed features of endometrial adenocarcinoma.
  • Follow-up total abdominal hysterectomy revealed bilateral luteinized thecomas of the ovary, one of which had undergone massive ossification converting the ovary into a bone.
  • True bone formation in ovarian tumors is rare.
  • This case is the second in the literature of osseous metaplasia in an ovarian luteinized thecoma, with the association of endometrial adenocarcinoma suggesting its functional status.
  • [MeSH-major] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Ovarian Neoplasms / pathology. Thecoma / complications. Thecoma / diagnosis. Uterine Neoplasms / pathology
  • [MeSH-minor] Aged. Endometrium / pathology. Female. Humans. Hysterectomy. Luteinization. Ossification, Heterotopic. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19332920.001).
  • [ISSN] 0974-5130
  • [Journal-full-title] Indian journal of pathology & microbiology
  • [ISO-abbreviation] Indian J Pathol Microbiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  •  go-up   go-down


41. Papathanasiou K, Tolikas A, Dovas D, Kostopoulou E, Fragkedakis N, Tzafettas J: Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology. Int J Gynecol Cancer; 2005 Nov-Dec;15(6):1191-4
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Simultaneously detected primary malignant tumors of ovary and endometrium with unusual histology.
  • A case of a mucinous adenocarcinoma of the ovary with a synchronous endometroid tumor of the endometrium with focal features of undifferentiated carcinoma and deep myometrial invasion is reported.
  • A review of the literature revealed that our case is interesting in view of the fact that simultaneous presentation of primary ovarian and endometrial neoplasms is rare and usually related to low-stage ovarian lesions and well-differentiated and superficial endometrial carcinomas in contrast to our case with the focal features of undifferentiated carcinoma and the deep myometrial invasion.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16343211.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


42. Mukonoweshuro P, Oriowolo A: Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma. Gynecol Oncol; 2005 Oct;99(1):222-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stromal osseous metaplasia in a low-grade ovarian adenocarcinoma.
  • BACKGROUND: Stromal osseous metaplasia is a rare and curious finding in tumors of the ovary.
  • CASE REPORT: The patient, a 66-year-old P3 G3 white female, had a past history of stage 1c left ovarian, well-differentiated endometrioid adenocarcinoma removed in 1981.
  • DISCUSSION: The pathogenesis of osseous metaplasia in epithelial tumors of the ovary is unclear; however, it is probable that a metaplastic process involving multipotential stromal stem cells results in bone formation.
  • CONCLUSION: Benign osseous metaplasia in ovarian tumors is rare and its histogenesis remains unclear.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16023183.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


43. Hayasaka T, Nakahara K, Kojimahara T, Saito-Sekiguchi M, Motoyama T, Kurachi H: Endometrioid adenocarcinoma with a functioning stroma. J Obstet Gynaecol Res; 2007 Jun;33(3):381-3
Hazardous Substances Data Bank. MENOTROPINS .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometrioid adenocarcinoma with a functioning stroma.
  • A case of a 70-year-old woman with endometrioid adenocarcinoma of the ovary with functioning stroma is presented.
  • The surgical specimens consisted of a multilocular cystic ovarian tumor of 95 mm in diameter and an enlarged uterus.
  • Histologically, the tumor was composed of proliferating, atypical, columnar cancer cells resembling early secretory endometrial cells, and condensation of plumed stromal cells resembling theca lutein cells.
  • The diagnosis of endometrial adenocarcinoma of the ovary with functioning stroma was made.
  • Almost all types of ovarian tumor have been reported to be associated with endocrine abnormalities.
  • Mucinous epithelial ovarian tumors most commonly present with estrogenic stroma, although the frequency of endometrioid adenocarcinoma with functioning stroma is very low.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Estradiol / blood. Follicle Stimulating Hormone / blood. Ovarian Neoplasms / pathology. Ovary / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. ESTRADIOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17578372.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 4TI98Z838E / Estradiol; 9002-68-0 / Follicle Stimulating Hormone
  •  go-up   go-down


44. Kir G, Gurbuz A, Karateke A, Kir M: Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma. World J Gastrointest Surg; 2010 Apr 27;2(4):109-16

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and immunohistochemical profile of ovarian metastases from colorectal carcinoma.
  • Metastasis of colorectal adenocarcinoma of the ovary is not an uncommon occurrence and ovarian metastases from colorectal carcinoma frequently mimic endometrioid and mucinous primary ovarian carcinoma.
  • The clinical and pathologic features of metastatic colorectal adenocarcinoma involving the ovary is reviewed with particular focus on the diagnostic challenge of distinguishing these secondary ovarian tumors from primary ovarian neoplasm.
  • Immunohistochemical stains that may be useful in the differential diagnosis of metastatic colorectal tumors to the ovary and primary ovarian tumors are detailed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21160859.001).
  • [ISSN] 1948-9366
  • [Journal-full-title] World journal of gastrointestinal surgery
  • [ISO-abbreviation] World J Gastrointest Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2999225
  • [Keywords] NOTNLM ; Colon / Colorectal carcinoma / Endometrioid adenocarcinoma / Immunohistochemistry / Metastatic carcinoma / Mucinous carcinoma / Ovary
  •  go-up   go-down


45. Yamano T, Morii E, Arai I, Takada T, Kubota K, Sato M, Inoue T, Okada Y, Hara T, Aozasa K: Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis. Int J Clin Oncol; 2010 Dec;15(6):621-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of primary versus metastatic ovarian adenocarcinoma using p53 gene mutation analysis.
  • Distinguishing primary ovarian cancer from metastatic colorectal cancer is often difficult by a conventional pathological examination alone.
  • We assessed the usefulness of p53 gene mutation analysis for the differential diagnosis of ovarian adenocarcinoma.
  • A 66-year-old woman suffered multiple organ metastases, including the liver, para-aortic lymph node, and right ovary, following an operation for advanced sigmoid colon cancer.
  • She underwent ovarian resection after effective chemotherapy against the liver and para-aortic lymph node cancer.
  • Histological analysis suggested primary ovarian cancer.
  • Therefore, we applied p53 gene mutation analysis for the differential diagnosis of primary versus metastatic ovarian cancer from sigmoid colon cancer.
  • The direct sequence of the p53 gene demonstrated the same gene mutation in codon 211 (ACT to ATT) in both the sigmoid colon and ovarian cancers.
  • According to the International Agency for Research on Cancer TP53 mutation database, this type of p53 mutation in colorectal cancer and ovarian cancer is 0.13% (5/3,693) and 0% (0/1,494), respectively.
  • Therefore, we determined that the ovarian tumor was metastatic.
  • Although p53 gene mutation analysis has been applied in some cases, this modality is very useful for the differential diagnosis of primary and metastatic cancer.
  • [MeSH-major] Liver Neoplasms / genetics. Liver Neoplasms / secondary. Mutation / genetics. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / secondary. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / genetics. Diagnosis, Differential. Female. Humans. Lymphatic Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514505.001).
  • [ISSN] 1437-7772
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


46. Saglam A, Bozdag G, Kuzey GM, Kuçukali T, Ayhan A: Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube. Arch Gynecol Obstet; 2008 Jun;277(6):557-62
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Four synchronous female genital malignancies: the ovary, cervix, endometrium and fallopian tube.
  • OBJECTIVE: To present a unique case of a 63 year-old woman with coexistent adenocarcinoma of the ovary, endometrium, cervix and fallopian tube.
  • The frozen section of the mass on the right adnex revealed malign mucinous carcinoma of the ovary.
  • As usual, optimal debulking was performed as initial surgical staging procedure of ovarian cancer.
  • The microscopic examination of the right ovary revealed a typical mucinous cystadenocarcinoma.
  • The pale infiltrative lesion in the cervix also turned out to be an adenocarcinoma of the endocervical type with deep stromal invasion and areas of diffuse glandular dysplasia and in-situ glandular neoplasia at the periphery.
  • Besides, several sections from the left fallopian tube uncovered diffuse dysplasia in the lining epithelium and a focus of adenocarcinoma with papillary and cribriform pattern.
  • [MeSH-major] Adenocarcinoma / pathology. Endometrial Neoplasms / pathology. Fallopian Tube Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18066567.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


47. Brahmania M, Kanthan CS, Kanthan R: Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor. World J Surg Oncol; 2007;5:118
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Collision tumor of the colon--colonic adenocarcinoma and ovarian granulosa cell tumor.
  • We report the first case, to our knowledge in the English literature, of a collision tumor composed of a colonic adenocarcinoma arising in a sigmoid diverticulum coexisting with a recurrent ovarian granulosa cell tumor.
  • Surgical removal of the mass and pathological examination revealed the presence of a colonic adenocarcinoma arising in a large sigmoid diverticulum coexistent with a second neoplastic tumor phenotype; confirmed to be a delayed recurrent ovarian granulosa cell tumor.
  • She developed lung metastases from the recurrent ovarian tumor within 6 months and died within a year of follow-up.
  • This is the first case reported of a collision tumor composed of adenocarcinoma colon and recurrent granulosa cell tumor representing an example of two independent tumors in a unique one-on-another collision.
  • As seen in our case, the delayed recurrence of granulosa cell tumor of the ovary sixteen years after the initial presentation was the key determining factor in tumor recurrence, tumor progression, and tumor metastasis within three months, which ultimately lead to accelerated death within a year of clinical presentation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Colonic Neoplasms / diagnosis. Granulosa Cell Tumor / diagnosis. Neoplasms, Multiple Primary / diagnosis. Ovarian Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ceska Gynekol. 2000 May;65(3):163-6 [10953492.001]
  • [Cites] Rom J Morphol Embryol. 2007;48(1):75-8 [17502956.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1180-9 [12637488.001]
  • [Cites] Pathol Oncol Res. 2003;9(3):188-92 [14530814.001]
  • [Cites] Cancer. 1976 Jul;38(1):335-40 [181131.001]
  • [Cites] Dis Colon Rectum. 1984 Dec;27(12):822-4 [6389052.001]
  • [Cites] Gastroenterol Clin Biol. 1990;14(2):185-6 [2328885.001]
  • [Cites] Surgery. 1993 Feb;113(2):223-6 [8430371.001]
  • [Cites] J Surg Oncol. 1994 Feb;55(2):71-7 [8121188.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):484-8 [8774662.001]
  • [Cites] Pathol Int. 1996 Jul;46(7):538-9 [8870012.001]
  • [Cites] Indian J Gastroenterol. 1997 Jan;16(1):28-9 [9167378.001]
  • [Cites] Arch Pathol Lab Med. 1998 Mar;122(3):262-5 [9823866.001]
  • [Cites] Surg Oncol. 2005 Jul;14(1):11-25 [15777886.001]
  • [Cites] Dig Dis Sci. 2002 Dec;47(12):2758-9 [12498297.001]
  • (PMID = 17949502.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2164962
  •  go-up   go-down


48. Kawano K, Ushijima K, Fujimoto T, Komai K, Kamura T: Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer. J Obstet Gynaecol Res; 2007 Jun;33(3):392-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Peptide YY producing strumal carcinoid of the ovary as the cause of severe constipation with contralateral epithelial ovarian cancer.
  • Primary ovarian carcinoid tumors are rare.
  • It has been reported that constipation was a presenting symptom in some patients with ovarian carcinoid.
  • A case of strumal carcinoid of the ovary with contralateral clear cell adenocarcinoma of the ovary discovered with a complaint of constipation is described.
  • Interestingly, the constipation caused by PYY also helped in discovering epithelial ovarian cancer.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Carcinoid Tumor / metabolism. Constipation / etiology. Ovarian Neoplasms / metabolism. Peptide YY / metabolism
  • [MeSH-minor] Female. Humans. Middle Aged. Neoplasms, Multiple Primary / complications. Neoplasms, Multiple Primary / metabolism. Neoplasms, Multiple Primary / pathology. Ovary / pathology


49. McCluggage WG, Hurrell DP, Kennedy K: Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases. Am J Surg Pathol; 2010 May;34(5):735-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ: report of a series of cases.
  • A variety of other neoplasms rarely metastasize to the cervix and, in most cases, the diagnosis is straightforward because of a combination of clinical and pathologic parameters, common features of metastatic carcinoma within the cervix including predominant involvement of the deep stroma, absence of surface involvement and of an in situ component, and prominent lymphovascular permeation.
  • We describe 6 cases of metastatic adenocarcinoma involving the cervix with superficial "mucosal" involvement mimicking primary cervical adenocarcinoma or adenocarcinoma in situ.
  • In 5 cases, the primary adenocarcinoma was in the ovary or peritoneum and was of serous (4 cases) or clear-cell (1 case) type.
  • In the other case, the primary neoplasm was in the pancreas and this was initially interpreted as a primary cervical adenocarcinoma.
  • In the cases of primary ovarian or peritoneal carcinoma, the mucosal tumor within the cervix, which was discovered at the same time as the ovarian or peritoneal neoplasm, raised the possibility of synchronous independent lesions or metastasis from the cervix to the ovary or peritoneum.
  • In those cases with an ovarian or peritoneal primary, the likely pathogenesis of the cervical involvement is transtubal and intrauterine spread.
  • It is important for the pathologist to be aware of the possibility of cervical mucosal metastasis to avoid an erroneous diagnosis of a primary cervical adenocarcinoma or adenocarcinoma in situ.
  • [MeSH-major] Carcinoma in Situ / diagnosis. Cystadenocarcinoma, Serous / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis. Peritoneal Neoplasms / diagnosis. Uterine Cervical Neoplasms / diagnosis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Middle Aged


50. Aoki D, Suzuki N, Susumu N, Noda T, Suzuki A, Tamada Y, Higashiguchi A, Oie S, Nozawa S: Establishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma. Hum Cell; 2005 Sep;18(3):143-6
Cellosaurus - a cell line knowledge resource. culture/stock collections - RMG-V (CVCL_M716) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of the RMG-V cell line from human ovarian clear cell adenocarcinoma.
  • A cell line, designated as RMG-V, was established from a patient with clear cell adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Cell Proliferation. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17022146.001).
  • [ISSN] 0914-7470
  • [Journal-full-title] Human cell
  • [ISO-abbreviation] Hum. Cell
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


51. McCluggage WG, Wilkinson N: Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features. Histopathology; 2005 Sep;47(3):231-47
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic neoplasms involving the ovary: a review with an emphasis on morphological and immunohistochemical features.
  • The ovary is a common site of metastatic tumour.
  • In many cases of ovarian metastasis there is a known history of malignancy but in other cases the ovarian tumour is the first manifestation of disease.
  • In this review metastatic colorectal, appendiceal, gastric, breast, pancreatic and biliary tract, hepatocellular, renal, transitional and cervical carcinomas and metastatic malignant melanoma involving the ovary are discussed, as is the issue of synchronous ovarian and endometrial carcinomas.
  • Peritoneal tumours, including primary peritoneal carcinoma, mesothelioma and intra-abdominal desmoplastic small round cell tumour, involving the ovary are also discussed, together with a variety of other rare, metastatic ovarian neoplasms.
  • Many metastatic adenocarcinomas involving the ovary, especially those exhibiting mucinous differentiation, closely mimic primary ovarian adenocarcinomas with morphologically bland areas simulating benign and borderline cystadenoma.
  • In recent years immunohistochemistry, especially but not exclusively differential cytokeratin (CK7 and CK20) staining, has been widely used as an aid to distinguish between a primary and secondary ovarian adenocarcinoma.
  • While immunohistochemistry undoubtedly has a valuable role to play and is paramount in diagnosis in some cases, the results must be interepreted with caution, especially in mucinous tumours, and within the relevant clinical context.
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / secondary
  • [MeSH-minor] Female. Humans. Immunohistochemistry. Intermediate Filament Proteins / analysis. Keratin-20. Keratin-7. Keratins / analysis. Ovary / chemistry. Ovary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16115224.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Intermediate Filament Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 68238-35-7 / Keratins
  • [Number-of-references] 114
  •  go-up   go-down


52. Dede M, Gezginç K, Alanbay I, Fidan U, Yenen M: A sarcomatous-type peritoneal malign mixed mullerian tumor implant in association with ovarian adenocarcinoma: a case report. Eur J Gynaecol Oncol; 2008;29(2):193-5
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A sarcomatous-type peritoneal malign mixed mullerian tumor implant in association with ovarian adenocarcinoma: a case report.
  • A rare case of a patient with a histopathological diagnosis of a sarcomatous-type peritoneal malign mixed müllerian tumor implant in association with ovarian adenocarcinoma is reported.
  • At transvaginal ultrasonographic examination, it was observed that there was an 80 x 70 mm sized, irregularly contoured, semisolid mass with hyperechogenous areas inside originating from the ovary in the right adnexal area.
  • Postoperative histopathological diagnosis was reported as malignant mixed mullerian tumor of the ovary, with the ovarian component as poorly differentiated adenocarcinoma, and the metastatic foci over serosal surfaces as a sarcomatous component.
  • [MeSH-major] Adenocarcinoma / complications. Mixed Tumor, Mullerian / complications. Ovarian Neoplasms / complications. Peritoneal Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18459565.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


53. Nishimura N, Hachisuga T, Yokoyama M, Iwasaka T, Kawarabayashi T: Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary. J Obstet Gynaecol Res; 2005 Apr;31(2):120-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
  • AIM: To compare the survival and prognostic factors of patients with dual primary ovarian and endometrial cancers (primary group), and endometrial cancers metastatic to the ovaries (metastatic group).
  • METHODS: Thirty-six patients with gross tumors confined to the pelvis and of endometrioid adenocarcinoma subtype in both the endometrium and ovary were selected from our file of 546 Japanese women with endometrial carcinoma.
  • CONCLUSION: When encountering women with coexisting endometrioid carcinoma in the endometrium and ovary with gross tumor limited to the pelvis, more attention should be paid to LVSI of the tumor of the uterus as a poor prognostic indicator.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15771637.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


54. Shin JH, Bae JH, Lee A, Jung CK, Yim HW, Park JS, Lee KY: CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma. Jpn J Clin Oncol; 2010 Mar;40(3):208-13
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CK7, CK20, CDX2 and MUC2 Immunohistochemical staining used to distinguish metastatic colorectal carcinoma involving ovary from primary ovarian mucinous adenocarcinoma.
  • OBJECTIVE: Colorectal adenocarcinoma, the most common tumor that metastasizes to the ovary, is often difficult to distinguish from primary ovarian mucinous adenocarcinoma (POMA).
  • Obtaining the correct diagnosis is difficult but crucial to treatment and prognosis.
  • METHODS: We evaluated the immunohistochemical (IHC) expression of cytokeratin 7 (CK7), cytokeratin 20 (CK20), CDX2, CEA, MUC2, MUC5AC and alpha-methylacyl-CoA racemase (AMACR) in 22 POMAs and 41 metastatic colorectal adenocarcinomas (MCAOs) involving ovaries.
  • [MeSH-major] Adenocarcinoma, Mucinous / metabolism. Colorectal Neoplasms / metabolism. Homeodomain Proteins / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism. Mucin-2 / metabolism. Ovarian Neoplasms / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Diagnosis, Differential. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate. Tissue Array Analysis. Young Adult

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19926591.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2
  •  go-up   go-down


55. Güney M, Oral B, Demir F, Ozsoy M, Kapucuoğlu N: Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report. Eur J Gynaecol Oncol; 2006;27(3):304-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma arising from the gastrointestinal epithelium in benign cystic teratoma of the ovary--case report.
  • Benign cystic teratoma of the ovary (BCTO) is the most common ovarian germ cell tumor occurring predominantly in early adulthood.
  • We present a rare case of adenocarcinoma arising from the gastrointestinal epithelial elements of BCTO based on the microscopic examination and immunohistochemical studies.
  • Adenocarcinoma arising from gastrointestinal epithelium within BCTOs is extremely rare.
  • This is the fifth reported case of adenocarcinoma arising in gastrointestinal epithelium of a BCTO.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16800267.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


56. Hess KR, Varadhachary GR, Taylor SH, Wei W, Raber MN, Lenzi R, Abbruzzese JL: Metastatic patterns in adenocarcinoma. Cancer; 2006 Apr 1;106(7):1624-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic patterns in adenocarcinoma.
  • The authors analyzed clinical data from a large number of patients with histologically confirmed, distant-stage adenocarcinoma to evaluate metastatic patterns.
  • RESULTS: Three primary tumors had single, dominant metastatic sites: ovary to abdominal cavity (91%), prostate to bone (90%), and pancreas to liver (85%).
  • In a study of combinations of liver, abdominal cavity, and bone metastases, 86% of prostate primary tumors had only bone metastases, 80% of ovarian primary tumors had only abdominal cavity metastases, and 74% of pancreas primary tumors had only liver metastases.
  • [MeSH-major] Adenocarcinoma / secondary. Algorithms. Neoplasm Metastasis. Registries / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2006 American Cancer Society.
  • (PMID = 16518827.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Walsh DJ, Sills ES, Shkrobot LV, Gleeson NC, Sheppard MN, Walsh AP: Ovarian serous adenocarcinoma identified during IVF: diagnostic approach, surgical management, and reproductive outcome. World J Surg Oncol; 2009;7:46
MedlinePlus Health Information. consumer health - Tumors and Pregnancy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ovarian serous adenocarcinoma identified during IVF: diagnostic approach, surgical management, and reproductive outcome.
  • BACKGROUND: To present a diagnostic evaluation and treatment strategy for serous adenocarcinoma of the ovary discovered during an in vitro fertilisation (IVF) sequence, and report on reproductive outcome after tumour resection and embryo transfer.
  • CASE PRESENTATION: Cycle monitoring in IVF identified an abnormal ovarian lesion which was subjected to ultrasound-guided needle aspiration.
  • No recurrence of cancer has been detected in the >72 month follow-up interval; mother and twin daughters continue to do well.
  • CONCLUSION: Suspicious adnexal structures noted during controlled ovarian hyperstimulation for IVF warrant assessment, and this report confirms the role of aspiration cytology in such cases.
  • [MeSH-major] Cystadenocarcinoma, Serous / surgery. Fertilization in Vitro. Ovarian Neoplasms / surgery. Pregnancy Complications, Neoplastic / surgery

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1992 Jan-Feb;36(1):11-8 [1546506.001]
  • [Cites] Clin Exp Obstet Gynecol. 2004;31(3):191-3 [15491061.001]
  • [Cites] Am J Obstet Gynecol. 1999 Mar;180(3 Pt 1):550-3 [10076126.001]
  • [Cites] Diagn Cytopathol. 1996 Nov;15(4):341-4 [8982593.001]
  • [Cites] Acta Cytol. 1996 Sep-Oct;40(5):911-20 [8842166.001]
  • [Cites] Int J Gynecol Pathol. 1996 Apr;15(2):94-101 [8786211.001]
  • [Cites] Fertil Steril. 1992 Jun;57(6):1274-8 [1601150.001]
  • [Cites] Acta Cytol. 2003 Nov-Dec;47(6):1059-62 [14674080.001]
  • (PMID = 19442277.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2689217
  •  go-up   go-down


58. Krepinska E, Kriz JT, Laco J: Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman. Eur J Gynaecol Oncol; 2010;31(5):584-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • Synchronous primary cancers of the endometrium and ovary occur in approximately 10% of all women with ovarian cancer and 5% of all women with endometrial cancer.
  • The pathogenesis of synchronous endometrial and ovarian cancer is unclear.
  • We report a case of unusual co-existence of endometroid adenocarcinoma of the uterus, serous borderline tumor of the ovary and Brenner tumor of the contralateral ovary in a 63-year-old woman.
  • [MeSH-major] Brenner Tumor / pathology. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21061809.001).
  • [ISSN] 0392-2936
  • [Journal-full-title] European journal of gynaecological oncology
  • [ISO-abbreviation] Eur. J. Gynaecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


59. Jung ES, Bae JH, Lee A, Choi YJ, Park JS, Lee KY: Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality. J Korean Med Sci; 2010 Feb;25(2):220-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma involving the ovary: comparative evaluation of the classification algorithms using tumor size and laterality.
  • For intraoperative consultation of mucinous adenocarcinoma involving the ovary, it would be useful to have approaching methods in addition to the traditional limited microscopic findings in order to determine the nature of the tumors.
  • Mucinous adenocarcinomas involving the ovaries were evaluated in 91 cases of metastatic mucinous adenocarcinomas and 19 cases of primary mucinous adenocarcinomas using both an original algorithm (unilateral >or=10 cm tumors were considered primary and unilateral <10 cm tumors or bilateral tumors were considered metastatic) and a modified cut-off size algorithm.
  • The diagnostic algorithm using size and laterality, in addition to clinical history, preoperative image findings, and operative findings, is a useful adjunct tool for differentiation of metastatic mucinous adenocarcinomas from primary mucinous adenocarcinomas of the ovary.
  • [MeSH-major] Adenocarcinoma, Mucinous / classification. Algorithms. Ovarian Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1447-64 [11075847.001]
  • [Cites] J Korean Med Sci. 2009 Feb;24(1):114-9 [19270823.001]
  • [Cites] Int J Gynecol Pathol. 2002 Oct;21(4):391-400 [12352188.001]
  • [Cites] Am J Surg Pathol. 2003 Mar;27(3):281-92 [12604884.001]
  • [Cites] Am J Surg Pathol. 2003 Jul;27(7):985-93 [12826891.001]
  • [Cites] Obstet Gynecol. 1989 Dec;74(6):921-6 [2685680.001]
  • [Cites] Cancer. 1994 Oct 15;74(8):2329-40 [7922984.001]
  • [Cites] Am J Surg Pathol. 1999 Jun;23(6):617-35 [10366144.001]
  • [Cites] Gynecol Oncol. 2006 Apr;101(1):152-7 [16300822.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1130-9 [16931958.001]
  • [Cites] Mod Pathol. 2006 Nov;19(11):1421-8 [16980943.001]
  • [Cites] Am J Surg Pathol. 2008 Jan;32(1):128-38 [18162780.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):209-14 [17624989.001]
  • [Cites] Int J Gynecol Pathol. 2008 Jul;27(3):353-65 [18580313.001]
  • [Cites] Semin Diagn Pathol. 2001 Aug;18(3):161-235 [11554665.001]
  • (PMID = 20119573.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2811287
  • [Keywords] NOTNLM ; Adenocarcinoma, Mucinous / Metastatic / Ovarian Neoplasms / Pimary
  •  go-up   go-down


60. Baek WS, Kubba SV: Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary. Gynecol Oncol; 2008 Dec;111(3):544-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cauda equina syndrome due to leptomeningeal carcinomatosis of the ovary.
  • BACKGROUND: Serous cystadenocarcinoma is the most common malignant ovarian tumor.
  • 85% are associated with extraovarian spread at the time of diagnosis.
  • Cauda equina syndrome due to leptomeningeal ovarian serous cystadenocarcinomatosis is rare.
  • CASE: A 66-year-old female with stage IV ovarian papillary serous cystadenocarcinoma presented with perianal numbness and sphincter dysfunction.
  • CSF showed malignant cells consistent with metastatic ovarian adenocarcinoma.
  • CONCLUSION: Ovarian cancer metastasizng to the cauda equina should be highly suspected based on the clinical presentation alone, even with unremarkable imaging studies.
  • [MeSH-major] Carcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Meningeal Carcinomatosis / pathology. Ovarian Neoplasms / pathology. Polyradiculopathy / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18433846.001).
  • [ISSN] 1095-6859
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


61. Abe A, Furumoto H, Yoshida K, Nishimura M, Irahara M, Kudo E, Sano T: A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):168-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of ovarian endometrioid adenocarcinoma with a yolk sac tumor component.
  • Endometrioid adenocarcinoma of the ovary coexists very rarely with yolk sac tumor (YST).
  • This unusual mixed tumor is thought to be a rare variant of endometrioid ovarian carcinoma because of its aggressive behavior, lack of response to chemotherapy, and unfavorable prognosis.
  • We report a case of ovarian endometrioid adenocarcinoma with a YST component in a postmenopausal woman.
  • Cytokeratin7 and epithelial membrane antigen were negative in YST, but positive in endometrioid adenocarcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endodermal Sinus Tumor / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Yolk sac tumor.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. PLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17466041.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bridged Compounds; 0 / Taxoids; 0 / alpha-Fetoproteins; 11056-06-7 / Bleomycin; 1605-68-1 / taxane; 49DFR088MY / Platinum; 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


62. Song YJ, Ryu SY, Choi SC, Lee ED, Lee KH, Cho SY: Adenocarcinoma arising from the respiratory ciliated epithelium in a benign cystic teratoma of the ovary. Arch Gynecol Obstet; 2009 Oct;280(4):659-62
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from the respiratory ciliated epithelium in a benign cystic teratoma of the ovary.
  • Benign cystic teratoma of the ovary (BCTO) is the most common benign ovarian tumor, accounting for 15-20% of all ovarian tumors.
  • Adenocarcinoma arising from mature cystic teratoma is extremely rare.
  • We present the patient with a BCTO, where a malignant transformation of respiratory ciliated epithelium resulted in well differentiated adenocarcinoma.
  • Although respiratory epithelium is often found in BCTOs, adenocarcinoma arising from this cell type is uncommon.
  • To our knowledge, this is the fourth reported case of adenocarcinoma arising from the respiratory epithelium of a BCTO.
  • [MeSH-major] Adenocarcinoma / pathology. Ovarian Neoplasms / pathology. Ovary / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224233.001).
  • [ISSN] 1432-0711
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


63. Min KJ, Jee BC, Lee HS, Kim YB: Intestinal adenocarcinoma arising in a mature cystic teratoma of the ovary: a case report. Pathol Res Pract; 2006;202(7):531-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intestinal adenocarcinoma arising in a mature cystic teratoma of the ovary: a case report.
  • Gastrointestinal adenocarcinoma arising in mature cystic teratomas of the ovary is extremely rare.
  • We report a case of well-differentiated intestinal adenocarcinoma arising in a mature cystic teratoma of the ovary in a 77-year-old woman, presenting as acute abdomen with ovarian torsion.
  • [MeSH-major] Adenocarcinoma / pathology. Intestinal Neoplasms / pathology. Neoplasms, Multiple Primary. Ovarian Neoplasms / pathology. Teratoma / pathology

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16713128.001).
  • [ISSN] 0344-0338
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / MUC2 protein, human; 0 / Mucin-2; 0 / Mucins; 68238-35-7 / Keratins
  •  go-up   go-down


64. Gonçalves R, Linhares E, Albagli R, Valadão M, Vilhena B, Romano S, Ferreira CG: Occurrence of other tumors in patients with GIST. Surg Oncol; 2010 Dec;19(4):e140-3
Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Evaluate the presence of other tumors in cohort of patients with GIST treated at a cancer treatment referral center - INCA.
  • Immunohistological diagnosis was confirmed by a pathologist specialized in sarcomas.
  • The diagnosis of GIST was incidental in 6 cases and in one case the non-GIST tumor was incidental.
  • The non-GIST tumors were most frequent in the stomach (adenocarcinoma), in 4 cases (28.5%) and colon/rectum (adenocarcinoma) in 4 other cases.
  • The other sites involved were breast (ductal carcinoma), kidney (clear cell carcinoma), prostate (adenocarcinoma), endometrium (adenocarcinoma), ovary (adenocarcinoma) and adrenal (neuroblastoma), with one case each.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Aged. Brazil / epidemiology. Child. Colonic Neoplasms / epidemiology. Female. Follow-Up Studies. Humans. Incidence. Male. Middle Aged. Rectal Neoplasms / epidemiology. Retrospective Studies. Stomach Neoplasms / epidemiology. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20675121.001).
  • [ISSN] 1879-3320
  • [Journal-full-title] Surgical oncology
  • [ISO-abbreviation] Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  •  go-up   go-down


65. Huang YD, Hung YC, Yeh LS, Chiang IP, Zeng GC, Chang WC: Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma. Taiwan J Obstet Gynecol; 2006 Sep;45(3):264-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • OBJECTIVE: We report a rare case of synchronous cancer consisting of ovarian endometrioid adenocarcinoma and endocervical mucinous adenocarcinoma.
  • Histology showed moderately to poorly differentiated endometrioid adenocarcinoma of the right ovary with extensive lymphovascular permeation, as well as paraaortic and bilateral pelvic lymph node metastases.
  • Extensive tumor thrombi were observed in the lymphovascular channels of the left ovary, bilateral tubes and uterus.
  • Endocervical adenocarcinoma, < 3 mm in depth, was also identified on the cervix.
  • The final surgical-pathologic stage of ovarian endometrioid adenocarcinoma was stage IIIc and of endocervical mucinous adenocarcinoma was stage IA1.
  • CONCLUSION: The coexistence of primary neoplasms in the ovary and cervix is rare.
  • Diagnosis should be based on histologic examination and requires appropriate treatment for both tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / epidemiology. Carcinoma, Endometrioid / epidemiology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / epidemiology. Uterine Cervical Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17175478.001).
  • [ISSN] 1875-6263
  • [Journal-full-title] Taiwanese journal of obstetrics & gynecology
  • [ISO-abbreviation] Taiwan J Obstet Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


66. de França Neto AH, Rogatto S, Do Amorim MM, Tamanaha S, Aoki T, Aldrighi JM: Oncological repercussions of polycystic ovary syndrome. Gynecol Endocrinol; 2010 Oct;26(10):708-11
MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncological repercussions of polycystic ovary syndrome.
  • Polycystic ovary syndrome (PCOS) is a highly prevalent endocrine disorder that has been associated with insulin resistance and metabolic syndrome.
  • Evidence has suggested that PCOS may be associated with the appearance of certain types of cancer, particularly endometrial, ovarian and breast cancer.
  • [MeSH-major] Adenocarcinoma / etiology. Endometrial Neoplasms / etiology. Polycystic Ovary Syndrome / complications
  • [MeSH-minor] Breast Neoplasms / etiology. Female. Humans. Ovarian Neoplasms / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20528205.001).
  • [ISSN] 1473-0766
  • [Journal-full-title] Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
  • [ISO-abbreviation] Gynecol. Endocrinol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  •  go-up   go-down


67. Rasi A, Tajziehchi L, Shaianfar N: Metastatic carcinoma of the ovary presenting as zosteriform lesions. Arch Iran Med; 2007 Apr;10(2):250-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic carcinoma of the ovary presenting as zosteriform lesions.
  • Distant metastases are unusual at presentation and during the course of ovarian carcinoma.
  • Skin metastases may be the first presenting sign of metastatic carcinoma of the ovary.
  • Ovarian epithelial adenocarcinoma rarely metastasizes to the skin, and can be seen in less than 4% of patients.
  • The histology in most of the tumors is serous papillary adenocarcinoma (grade 1 or 2).
  • [MeSH-major] Adenocarcinoma / secondary. Ovarian Neoplasms / pathology. Skin Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17367234.001).
  • [ISSN] 1029-2977
  • [Journal-full-title] Archives of Iranian medicine
  • [ISO-abbreviation] Arch Iran Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Iran
  •  go-up   go-down


68. Hart WR: Borderline epithelial tumors of the ovary. Mod Pathol; 2005 Feb;18 Suppl 2:S33-50
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Borderline epithelial tumors of the ovary.
  • The concept and terminology of borderline epithelial tumors of the ovary have been controversial for over a century, in spite of the acceptance of a borderline category in almost all current classifications of ovarian tumors.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15761465.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 93
  •  go-up   go-down


69. Rodina AV, Sladkova LV, Obukhova VV, Vezirkhanova TZ, Moskaleva EIu, Prusakova OV, Beletskiĭ IP, Belushkina NN, Strel'nikov VV, Ivanov MA, Severin SE, Severin ES: [Inactivation and sensitization of the tumor cells by the gene Bax transfection]. Mol Biol (Mosk); 2005 Jan-Feb;39(1):40-7
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • After the transfection of the gene Bax into the cultured tumor cells of human ovary adenocarcinoma SKOV3 and uterus carcinoma HeLa in vitro the high sensitivity of the cells SKOV3 to the protein Bax produced after the gene Bax transfection was found.
  • [MeSH-minor] Adenocarcinoma. Antibiotics, Antineoplastic / pharmacology. Cell Survival. Doxorubicin / pharmacology. Drug Resistance, Neoplasm. Female. Green Fluorescent Proteins / biosynthesis. Green Fluorescent Proteins / genetics. Humans. Liposomes. Mutation. Ovarian Neoplasms. Tumor Cells, Cultured. Uterine Cervical Neoplasms. bcl-2-Associated X Protein

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15773546.001).
  • [ISSN] 0026-8984
  • [Journal-full-title] Molekuliarnaia biologiia
  • [ISO-abbreviation] Mol. Biol. (Mosk.)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / BAX protein, human; 0 / Liposomes; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; 147336-22-9 / Green Fluorescent Proteins; 80168379AG / Doxorubicin
  •  go-up   go-down


70. Virk R, Lu D: Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary. Pathol Res Pract; 2010 Jul 15;206(7):489-92
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucinous adenocarcinoma as heterologous element in intermediately differentiated Sertoli-Leydig cell tumor of the ovary.
  • Sertoli-Leydig cell tumor (SLCT) is a rare tumor involving the ovary.
  • However, SLCT with mucinous adenocarcinoma as heterologous element has been rarely documented.
  • Herein, we describe a rare case of intermediately differentiated Sertoli-Leydig cell tumor with mucinous adenocarcinoma as the heterologous element in a 21-year-old woman.
  • She presented with throbbing lower abdominal pain and was found to have a large, complex left ovarian mass on imaging studies.
  • Gross examination of the surgical specimen showed a large, encapsulated, solid-cystic mass completely replacing the ovary.
  • Microscopically, the tumor was composed of intermediately differentiated Sertoli-Leydig cell tumor and well-differentiated mucinous adenocarcinoma.
  • Interestingly, the bulk of the tumor (more than 90%) was composed of mucinous adenocarcinoma, whereas the SLCT component comprised less than 10% of the total tumor.
  • The mucinous adenocarcinoma expressed positivity for CK20, CEA, CDX2 and CK7, and the SLCT component was positive for inhibin expression.
  • The histopathological features and results of immunostaining were consistent with the diagnosis of the intermediately differentiated SLCT with mucinous adenocarcinoma as the heterologous element.
  • This case was a diagnostic challenge as more than 90% of the tumor was composed of mucinous adenocarcinoma and SLCT constituted only the minor part of the tumor.
  • This feature was in contrast to the previously described two cases, where mucinous adenocarcinoma as heterologous element was present as microscopic foci.
  • This case highlights the importance of identifying the SLCT component in a case of an apparently pure mucinous adenocarcinoma in a young patient.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Ovarian Neoplasms / pathology. Sertoli-Leydig Cell Tumor / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009. Published by Elsevier GmbH.
  • (PMID = 19674851.001).
  • [ISSN] 1618-0631
  • [Journal-full-title] Pathology, research and practice
  • [ISO-abbreviation] Pathol. Res. Pract.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


71. Ozbey C, Erdogan G, Pestereli HE, Simsek T, Karaveli S: Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case. APMIS; 2005 Oct;113(10):713-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous papillary adenocarcinoma and adult granulosa cell tumor in the same ovary. An unusual case.
  • Surface epithelial-stromal cell tumors are the most common neoplasms of the ovary but occurrence of a serous adenocarcinoma and an adult granulosa cell tumor in the same ovary is an unusual incident.
  • In the present case report we describe this very uncommon occurrence in the ovary of a 50-year-old woman.
  • Microscopy revealed an adult granulosa cell tumor and a serous papillary adenocarcinoma in the left ovary.
  • Immunohistochemical staining with inhibin alpha and pancytokeratin confirmed the diagnosis.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Granulosa Cell Tumor / pathology. Ovarian Neoplasms / pathology. Ovary / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] APMIS. 2007 Jun;115(6):769-71 [17550386.001]
  • (PMID = 16309432.001).
  • [ISSN] 0903-4641
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / inhibin-alpha subunit; 57285-09-3 / Inhibins; 68238-35-7 / Keratins
  •  go-up   go-down


72. Ferrandina G, Carbone A, Zannoni GF, Martinelli E, Testa AC, Gallotta V, De Ninno M, Scambia G: Serous ovarian carcinoma recurring as a heterologous carcinosarcoma. J Obstet Gynaecol Res; 2007 Feb;33(1):95-9
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous ovarian carcinoma recurring as a heterologous carcinosarcoma.
  • Only two cases of recurrence of heterologous carcinosarcoma from adenocarcinoma of the ovary have been documented in the published literature.
  • We report a case of serous ovarian carcinoma recurring as a heterologous carcinosarcoma.
  • The immunohistochemical analysis of several biological parameters in primary ovarian adenocarcinoma and recurrent carcinosarcoma has been also performed.
  • [MeSH-major] Carcinosarcoma / pathology. Cystadenocarcinoma, Serous / pathology. Ovarian Neoplasms / pathology

  • Genetic Alliance. consumer health - Ovarian carcinosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212675.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


73. Yasuoka H, Tsujimoto M, Fujita S, Yamasaki T, Kashihara H, Nishio Y, Kodama R, Inagaki M, Oishi H, Sanke T, Nakamura Y: Coexistence of a clear cell adenocarcinoma and an adenosarcoma with a heterologous rhabdomyosarcoma in an endometriotic cyst of the ovary: a case study. Int J Gynecol Pathol; 2009 Jul;28(4):362-6
MedlinePlus Health Information. consumer health - Ovarian Cysts.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistence of a clear cell adenocarcinoma and an adenosarcoma with a heterologous rhabdomyosarcoma in an endometriotic cyst of the ovary: a case study.
  • SUMMARY: A rare case of a clear cell adenocarcinoma and an adenosarcoma coexisting with a heterologous rhabdomyosarcoma in an endometriotic cyst of the ovary is reported.
  • The cyst wall was lined with a single layer of endometrial-type cells, whereas the solid area was composed of a clear cell adenocarcinoma.
  • Using X-chromosomal clonality assay, these clear cell adenocarcinoma and adenosarcoma components showed patterns of polyclonality.
  • To the authors' knowledge, this is the first reported case of a clear cell adenocarcinoma and an adenosarcoma coexisting with heterologous rhabdomyosarcoma in an endometriotic cyst of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Adenosarcoma / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Cysts / pathology. Ovarian Neoplasms / pathology. Rhabdomyosarcoma / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19483627.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Receptors, Androgen
  •  go-up   go-down


74. Chiang YC, Chen CA, Huang CY, Hsieh CY, Cheng WF: Synchronous primary cancers of the endometrium and ovary. Int J Gynecol Cancer; 2008 Jan-Feb;18(1):159-64
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous primary cancers of the endometrium and ovary.
  • Simultaneous detection of malignancy in the endometrium and ovary represents an uncommon event.
  • The histologic determination was followed by the World Health Organization Committee classification, and cancer stage was based on the staging system of the FIGO.
  • The incidence of synchronous primary endometrial and ovarian cancers was 3.3% in patients with endometrial cancer and 2.7% in patients with ovarian cancer.
  • We conclude that the majority of the patients belonged to concordant endometrioid histology in endometrium and ovary, and it tends to be early stage and low grade with favorable prognosis.
  • [MeSH-major] Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / secondary. Adenocarcinoma, Clear Cell / secondary. Adult. Carcinoma, Endometrioid / secondary. Cystadenocarcinoma, Serous / secondary. Female. Humans. Middle Aged. Prognosis. Retrospective Studies. Risk Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17506847.001).
  • [ISSN] 1525-1438
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Delotte J, Ferron G, Kuei TL, Mery E, Gladieff L, Querleu D: Laparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervix. J Minim Invasive Gynecol; 2009 Jan-Feb;16(1):106-8
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic management of an isolated ovarian metastasis on a transposed ovary in a patient treated for stage IB1 adenocarcinoma of the cervix.
  • Transposition of the ovaries is performed frequently in young women with early-stage cervical cancer.
  • However, this must be balanced with the risks of ovarian metastases especially in patients with adenocarcinomas.
  • We report the first case of laparoscopic management of an isolated metastasis to a transposed ovary that occurred 2 years after primary laparoscopic treatment of a stage IB1 adenocarcinoma of the cervix.
  • [MeSH-major] Adenocarcinoma / surgery. Laparoscopy / methods. Lymph Node Excision. Ovarian Neoplasms / secondary. Ovarian Neoplasms / surgery. Ovariectomy / methods. Uterine Cervical Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19110193.001).
  • [ISSN] 1553-4650
  • [Journal-full-title] Journal of minimally invasive gynecology
  • [ISO-abbreviation] J Minim Invasive Gynecol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Vrdoljak-Mozetic D, Stanković T, Krasević M, Versa-Ostojić D, Stemberger-Papić S, Rupcić S: Intraoperative cytology of clear cell carcinoma of the ovary. Cytopathology; 2006 Dec;17(6):390-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative cytology of clear cell carcinoma of the ovary.
  • OBJECTIVE: To describe the cytomorphology of clear cell carcinoma (CCC) of the ovary in intraoperative samples of peritoneal fluid, imprint and scraping samples of the tumour tissue.
  • CONCLUSION: Using cytological analysis of imprint and scraping samples of ovarian tumours it is possible to make a precise intraoperative cytological diagnosis in most cases of CCC of the ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17168923.001).
  • [ISSN] 0956-5507
  • [Journal-full-title] Cytopathology : official journal of the British Society for Clinical Cytology
  • [ISO-abbreviation] Cytopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Lewis MR, Euscher ED, Deavers MT, Silva EG, Malpica A: Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall. Gynecol Oncol; 2007 May;105(2):395-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall.
  • OBJECTIVES: Elevated serum levels of CA125 are observed not only in association with primary ovarian epithelial neoplasms but also in a variety of other clinical settings, including ovarian involvement by metastatic disease.
  • There is considerable overlap in gross and histologic features between primary ovarian tumors and metastatic colorectal adenocarcinoma, which can make diagnosis particularly challenging in the setting of an increased CA125 level.
  • The aims of this study were to determine how frequently serum CA125 is elevated in women with ovarian involvement by metastatic colorectal adenocarcinoma and to compare the features of cases with and without associated elevations of serum CA125.
  • METHODS: Eighty-nine cases of histologically confirmed ovarian involvement by metastatic colorectal adenocarcinoma were identified by retrospective review.
  • In three cases, the tumor was initially diagnosed as an ovarian primary.
  • CONCLUSIONS: At least 32.6% of women with ovarian involvement by metastatic colorectal adenocarcinoma have an elevated serum CA125 level prior to oophorectomy.
  • The possibility of metastasis from a colorectal carcinoma merits consideration in the formation of the differential diagnosis for a woman with an adnexal mass and elevated serum CA125, even in the absence of an established history of gastrointestinal malignancy.
  • [MeSH-major] Adenocarcinoma / blood. Adenocarcinoma / secondary. CA-125 Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. Ovarian Neoplasms / blood. Ovarian Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17335881.001).
  • [ISSN] 0090-8258
  • [Journal-full-title] Gynecologic oncology
  • [ISO-abbreviation] Gynecol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CA-125 Antigen
  •  go-up   go-down


78. Rollins SE, Young RH, Bell DA: Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma. Am J Surg Pathol; 2006 Apr;30(4):457-62
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimplants in serous borderline tumors of the ovary: a clinicopathologic study of 30 cases of a process to be distinguished from serous adenocarcinoma.
  • The clinical and pathologic features of serous borderline tumors (SBTs) with autoimplants (AIs) were studied with emphasis on their relation to survival, ovarian SBT with a micropapillary pattern, and their distinction from serous adenocarcinoma.
  • Twenty-five patients had bilateral ovarian tumors.
  • Features that favor AI over carcinoma arising in an SBT are 1) a location between tumor papillae or on the ovarian surface 2) a predominance of stroma over epithelial cells, and 3) the "borderline" cytologic appearance of epithelial cells.
  • [MeSH-major] Cystadenocarcinoma, Serous / pathology. Cystadenoma, Serous / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Humans. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16625091.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Benit A, Allard J, Rimailho J, Fauvel J, Escourrou G, Vezzosi D, Donadille F, Bennet A, Caron P: Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels. J Endocrinol Invest; 2006 May;29(5):443-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Persistent and moderate hypercalcemia related to an ovarian clear cell adenocarcinoma: Pre- and postoperative parathyroid hormone related-peptide and 1,25-dihydroxyvitamin D3 levels.
  • OBJECTIVE: To evaluate the role of PTH-related peptide (PTH-rP) and 1,25-dihyhydroxyvitamin D3 in a case of hypercalcemia related to an ovarian adenocarcinoma.
  • DESIGN: We report a case of humoral hypercalcemia in a patient aged 74 yr with a clear cell adenocarcinoma of the right ovary at an early stage of its development (stage T1aN0M0) revealed by moderate and persistent hypercalcemia (variable level between 2.7 and 3.2 mmol/l without any treatment) over six months.
  • METHODS: PTH-rP and 1,25-dihydroxyvitamin D3 were measured in blood samples taken before and after hysterectomy and bilateral salpingooophorectomy and in blood samples taken intraoperatively from the right ovarian vein and a peripheral vein.
  • A concentration gradient was found regarding plasma PTHrP (right ovarian vein 60.4 pmol/l, peripheral vein 4.5 pmol/l), not 1,25-dihydroxyvitamin D3.
  • CONCLUSION:. 1) moderate and persistent hypercalcemia can be observed at an early stage of an ovarian carcinoma;.
  • 2) the gradient of PTH-rP concentration between the samples taken from the right ovarian vein and a peripheral vein provides evidence for a direct secretion of PTH-rP by the ovarian tumor;.
  • 3) the increased 1,25-dihydroxyvitamin D3 level is not related to a direct ovarian production, but is a consequence of PTH-rP secretion.
  • [MeSH-major] Adenocarcinoma, Clear Cell / complications. Calcitriol / blood. Hypercalcemia / etiology. Ovarian Neoplasms / complications. Parathyroid Hormone-Related Protein / blood

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. 1,25-DIHYDROXYCHOLECALCIFEROL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16794368.001).
  • [ISSN] 0391-4097
  • [Journal-full-title] Journal of endocrinological investigation
  • [ISO-abbreviation] J. Endocrinol. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Parathyroid Hormone-Related Protein; FXC9231JVH / Calcitriol
  •  go-up   go-down


80. Chen F, Shen K, Lang JH, Huang HF, Wu M: [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary]. Zhonghua Yi Xue Za Zhi; 2005 May 18;85(18):1257-60
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and prognostic of double primary carcinoma of uterine corpus and the ovary].
  • OBJECTIVE: To investigate the clinical features, treatment and prognosis of patients with double primary carcinoma of uterine corpus and ovary.
  • METHODS: The clinical features, operation findings, treatment and prognosis of 36 patients with double primary carcinoma of uterine corpus diagnosed and treated in the last 20 years, 25 with typical endometrial adenocarcinoma and endometrioid carcinoma of the ovary (group A) 11 with non-endometrioid carcinoma in uterine corpus and/or ovary (group B) were respectively analyzed.
  • The 1, 3, and 5-year survival rates of these 36 patients were 89%, 83%, and 75% respectively, all equal to those of the patients with stage I ovarian cancer.
  • CONCLUSION: The prognosis of double primary carcinoma of uterine corpus and ovary is rather good.
  • It is necessary to distinguish double primary carcinoma of uterine corpus and ovary from stage II ovarian cancer and stage III endometrial carcinoma.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16029611.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


81. Terada T, Kawaguchi M: Primary clear cell adenocarcinoma of the peritoneum. Tohoku J Exp Med; 2005 Jul;206(3):271-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary clear cell adenocarcinoma of the peritoneum.
  • A 49-year-old Japanese woman underwent hysterectomy and bilateral salpingo-oophorectomy for endometrial endometrioid adenocarcinoma grade III, which was composed of undifferentiated carcinoma cells (98%) and tubular carcinoma cells (2%).
  • No clear cell adenocarcinoma elements were noted in this tumor.
  • The morphologies fulfilled the criteria of clear cell adenocarcinoma.
  • Our case was characterized by cyst formations and encapsulation in addition to the common histological features of clear cell adenocarcinoma of the uterus and ovary.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Peritoneal Neoplasms / diagnosis
  • [MeSH-minor] Cell Proliferation. Cytoplasm / metabolism. Endometrial Neoplasms / metabolism. Female. Humans. Hysterectomy. Immunohistochemistry. Middle Aged. Ovary / pathology. Periodic Acid-Schiff Reaction. Spleen / metabolism. Stomach / metabolism. Uterine Neoplasms. Uterus / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15942157.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Ma SK, Zhang HT, Sun YC, Wu LY: [Synchronous primary cancers of the endometrium and ovary: review of 43 cases]. Zhonghua Zhong Liu Za Zhi; 2008 Sep;30(9):690-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancers of the endometrium and ovary: review of 43 cases].
  • OBJECTIVE: To investigate the clinical and pathological characteristics, treatment methods, and prognosis of synchronous primary cancers of the endometrium and ovary.
  • METHODS: The clinical data of 43 patients with synchronous primary cancers of the endometrium and ovary were retrospectively reviewed.
  • RESULTS: The median age at diagnosis was 49 years (range, 28-73 years).
  • FIGO stages of endometrial carcinomas: IA 18 cases, IB 20 cases, IC 2 cases, IIA 3 cases; Stages of ovarian carcinomas: IA 19 cases, IB 4 cases, IC 7 cases, II 4 cases, III C 9 cases.
  • Twenty-four patients (55.8%) were in stage I both endometrial and ovarian carcinomas.
  • Thirty-eight of the 43 patients (88.4%) had a pathologically proven endometrial adenocarcinoma.
  • The predominant ovarian histology was endometrioid or mixed tumor with endometrioid components (30/43, 69.8%).
  • The 3- and 5-year survival rates of patients with both endometrioid and ovarian carcinomas were higher than that of those with non-endometrioid or mixed subtypes (93.8%, 82.0% vs. 79.7%, 69.0%).
  • CONCLUSION: Synchronous primary cancers of the endometrium and ovary are different from either primary endometrial carcinoma or ovarian cancer, while it can usually be detected in early stage and with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid. Endometrial Neoplasms. Hysterectomy / methods. Neoplasms, Multiple Primary. Ovarian Neoplasms

  • MedlinePlus Health Information. consumer health - Hysterectomy.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173912.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / NBR1 protein, human; 0 / Proteins
  •  go-up   go-down


83. McCoubrey A, Houghton O, McCallion K, McCluggage WG: Serous adenocarcinoma of the sigmoid mesentery arising in cystic endosalpingiosis. J Clin Pathol; 2005 Nov;58(11):1221-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous adenocarcinoma of the sigmoid mesentery arising in cystic endosalpingiosis.
  • This case report describes a Mullerian serous adenocarcinoma arising within a multoloculated cyst lined by ciliated serous-type epithelium located in the sigmoid mesentery.
  • The ovaries contained bilateral serous cystadenofibromas, and multiple cysts lined by ciliated serous-type epithelium were present in the omentum.
  • This was lined largely by benign ciliated serous-type epithelium but a focus of well differentiated serous adenocarcinoma projected into the lumen.
  • This is a unique case of multiple omental, peritoneal, and retroperitoneal cysts (classified as cystic endosalpingiosis), one of which developed a focus of serous adenocarcinoma.
  • Although rarely serous adenocarcinomas, similar to those occurring within the ovary, arise in the retroperitoneum, this is the first reported occurrence in association with a pre-existing benign lesion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Pathol. 2000 Feb;53(2):161-2 [10767837.001]
  • [Cites] Arch Gynecol Obstet. 2004 Dec;270(4):302-6 [14551796.001]
  • [Cites] J Clin Pathol. 2001 May;54(5):399-400 [11328842.001]
  • [Cites] Histopathology. 2001 Dec;39(6):645-6 [11903588.001]
  • [Cites] Hum Pathol. 2002 Sep;33(9):944-6 [12378522.001]
  • [Cites] Histopathology. 2004 Feb;44(2):109-15 [14764054.001]
  • [Cites] Int J Gynecol Pathol. 2004 Apr;23(2):97-9 [15084836.001]
  • [Cites] Obstet Gynecol Surv. 1972 Mar;27(3):133-46 [4614139.001]
  • [Cites] Am J Surg Pathol. 1982 Mar;6(2):109-17 [7102891.001]
  • [Cites] Am J Clin Pathol. 1983 May;79(5):633-7 [6188369.001]
  • [Cites] Int J Gynecol Pathol. 1989;8(3):179-88 [2475447.001]
  • [Cites] Eur J Radiol. 1993 Sep;17(2):115-6 [8223678.001]
  • [Cites] Gynecol Oncol. 1996 Mar;60(3):393-6 [8774644.001]
  • [Cites] Clin Radiol. 1998 Dec;53(12):916-8 [9867279.001]
  • [Cites] Am J Surg Pathol. 1999 Feb;23(2):166-75 [9989843.001]
  • [Cites] Int J Gynecol Pathol. 2000 Apr;19(2):158-63 [10782413.001]
  • (PMID = 16254118.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1770769
  •  go-up   go-down


84. Yahata T, Kawasaki T, Serikawa T, Suzuki M, Tanaka K: Adenocarcinoma arising from respiratory ciliated epithelium in benign cystic teratoma of the ovary: a case report with analyzes of the CT, MRI, and pathological findings. J Obstet Gynaecol Res; 2008 Jun;34(3):408-12
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenocarcinoma arising from respiratory ciliated epithelium in benign cystic teratoma of the ovary: a case report with analyzes of the CT, MRI, and pathological findings.
  • Adenocarcinoma occurs with less frequency.
  • We herein present a patient with an ovarian mature cystic teratoma who demonstrated a malignant transformation to well-differentiated adenocarcinoma.
  • Microscopically and immunohistochemically, the adenocarcinoma was considered to have arisen from the ciliated respiratory epithelium.
  • This is the third reported case of adenocarcinoma arising in the respiratory epithelium of an ovarian mature cystic teratoma.
  • Contrast enhanced CT and MRI are useful for making a preoperative diagnosis and an immunohistochemical study is helpful for defining its origin.
  • [MeSH-major] Adenocarcinoma / diagnosis. Infant. Magnetic Resonance Imaging. Ovarian Neoplasms / diagnosis. Teratoma / diagnosis. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18588616.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


85. Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H: Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep; 2009 Aug;22(2):233-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review).
  • Epithelial ovarian cancer (EOC) is the leading cause of death in women with gynecological malignancies.
  • Among EOC, clear cell carcinoma (CCC) and endometrioid adenocarcinoma (EAC) differ from the other histological types with respect to their clinical characteristics and carcinogenesis.
  • The present article reviews the English language literature for biological, pathogenetic and pathophysiological studies on endometriosis-associated CCC of the ovary.
  • Retrograde menstruation or ovarian hemorrhage carries highly pro-oxidant factors, such as heme and iron, into the peritoneal cavity or ovarian endometrioma.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19578761.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / F-Box Proteins; 0 / FBXO5 protein, human; 138674-15-4 / Hepatocyte Nuclear Factor 1-beta; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases
  • [Number-of-references] 56
  •  go-up   go-down


86. Silverman JF, Zhu B, Liu Y, Lin X: Distinctive immunohistochemical profile of mucinous cystic neoplasms of pancreas, ovary and lung. Histol Histopathol; 2009 01;24(1):77-82
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive immunohistochemical profile of mucinous cystic neoplasms of pancreas, ovary and lung.
  • Mucinous cystic neoplasms (MCNs) of the pancreas, ovary and lung have a similar histologic appearance.
  • Twenty-six ovarian MCNs (invasive carcinoma and borderline tumor), 12 pancreatic MCNs (invasive carcinoma, and with moderate or high-grade dysplasia), and 3 pulmonary MCNs (only invasive carcinoma) were retrieved.
  • The IHC profile of ovarian intestinal type MCN is similar to that of pancreatic MCNs, except for lower frequency of CDX-2 expression (29% vs. 67%).
  • Ovarian endocervical like MCNs are positive for CA-125 (100%) and CK7 (100%), while are negative for CDX-2, PDX-1 and CK20.
  • We concluded that an IHC panel of CDX-2, PDX-1, CA-125, and CK20 is useful in separating MCNs of the pancreas, ovary and lung.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Neoplasm Metastasis / diagnosis. Ovarian Neoplasms / diagnosis. Pancreatic Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19012247.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / CDX2 Transcription Factor; 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Trans-Activators; 0 / pancreatic and duodenal homeobox 1 protein
  •  go-up   go-down


87. Sugiyama K, Takehara Y: Magnetic resonance findings of clear-cell adenocarcinofibroma of the ovary. Acta Radiol; 2007 Jul;48(6):704-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Magnetic resonance findings of clear-cell adenocarcinofibroma of the ovary.
  • We report the magnetic resonance (MR) findings of clear-cell adenocarcinofibroma of the ovary.
  • Adenocarcinofibroma of the ovary is a rare tumor, but MR findings may be helpful to reach the correct diagnosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Fibroma / diagnosis. Magnetic Resonance Imaging / methods. Ovarian Neoplasms / diagnosis. Ovary / pathology
  • [MeSH-minor] Abdomen / pathology. Abdomen / ultrasonography. Abdominal Pain / etiology. Aged. Contrast Media / administration & dosage. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Image Enhancement / methods. Pelvis / pathology. Pelvis / ultrasonography. Rare Diseases

  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17611882.001).
  • [ISSN] 0284-1851
  • [Journal-full-title] Acta radiologica (Stockholm, Sweden : 1987)
  • [ISO-abbreviation] Acta Radiol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


88. Kato N, Sasou S, Motoyama T: Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary. Mod Pathol; 2006 Jan;19(1):83-9
MedlinePlus Health Information. consumer health - Ovarian Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary.
  • Clear cell tumors of the ovary are frequently associated with ovarian endometriosis.
  • Microarray analysis revealed recently that hepatocyte nuclear factor-1beta (HNF-1beta) was significantly upregulated in clear cell carcinoma of the ovary.
  • In the present study, we examined 30 clear cell tumors (26 malignant, three borderline, and one benign) and 40 endometriotic cysts to clarify if differentiation into the clear cell lineage already begins in ovarian endometriosis.
  • All of the 30 clear cell tumors, including borderline and benign ones, showed immunohistochemical expression of HNF-1beta in the nucleus, while other types of ovarian epithelial tumors (endometrioid, serous, mucinous, and Brenner tumors) rarely expressed it.
  • Our results indicate that HNF-1beta is an excellent molecular marker for ovarian clear cell tumors, including benign, borderline and malignant lesions.
  • Early differentiation into the clear cell lineage takes place in ovarian endometriosis, not only in atypical endometriosis, but also in endometriosis with degenerative and regenerative changes, and this is probably responsible for the frequent occurrence of clear cell carcinoma in ovarian endometriosis.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Endometriosis / pathology. Hepatocyte Nuclear Factor 1-beta / biosynthesis. Ovarian Diseases / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Epithelial Cells / chemistry. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Ovarian Cysts / metabolism. Ovarian Cysts / pathology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16258507.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 138674-15-4 / Hepatocyte Nuclear Factor 1-beta
  •  go-up   go-down


89. Lou HM, Lou HK, Wu MJ: [Synchronous primary cancer of the endometrium and ovary]. Zhonghua Zhong Liu Za Zhi; 2006 Aug;28(8):617-20
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synchronous primary cancer of the endometrium and ovary].
  • To investigate the clinical and pathological characteristics, treatment, and The data of 12 patients prognosis of synchronous primary cancer of the endometrium and ovary.
  • Methods with synchronous primary cancer of the endometrium and ovary were retrospectively reviewed .
  • Results Eight patients had the same histological type of endometrioid carcinoma in both uterus and ovary, 4 patients had different histological types in uterus and ovary.
  • Synchronous primary cancer of the endometrium and ovary was difficult to be dignosed preoperatively.
  • All ovarian tumors were small with an average diameter of 7 cm.
  • CONCLUSION: Synchronous primary endometrium and ovary cancer is a specific kind of tumor different from either the primary endometrium carcinoma or ovary carcinoma, and usually can be detected in early stage with a good prognosis.
  • [MeSH-major] Carcinoma, Endometrioid / pathology. Endometrial Neoplasms / pathology. Neoplasms, Multiple Primary / pathology. Ovarian Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / therapy. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Cystadenocarcinoma, Papillary / pathology. Cystadenocarcinoma, Papillary / therapy. Female. Follow-Up Studies. Humans. Hysterectomy. Middle Aged. Retrospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17236559.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; CP protocol
  •  go-up   go-down


90. Kim MJ, Hong SM, Jang SJ, Yu E, Kim JS, Kim KR, Gong G, Ro JY: Invasive colorectal micropapillary carcinoma: an aggressive variant of adenocarcinoma. Hum Pathol; 2006 Jul;37(7):809-15
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Invasive colorectal micropapillary carcinoma: an aggressive variant of adenocarcinoma.
  • Micropapillary carcinoma (MC) has been well described in other organs, including breast, urinary bladder, lung, ovary, and salivary gland, but has not been described in the large intestine.
  • We compared the clinicopathologic and immunohistochemical findings of MC with those of conventional adenocarcinoma in the large intestine.
  • Fifty-five cases of adenocarcinoma with an MC component were identified among 585 consecutive cases of colorectal cancer at the Asan Medical Center between January 2003 and June 2004 and were compared with 119 cases of conventional adenocarcinoma of colorectum without an MC component.
  • The grade of both MC and conventional adenocarcinoma was mostly moderately differentiated.
  • The presence but not extent of MC in the primary tumors was associated with more frequent lymphovascular invasion and lymph node (LN) metastases, a greater mean number of positive LNs, and a higher tumor stage with more frequent distant metastases, compared with conventional adenocarcinoma (P < .05).
  • Cytokeratin 7 staining was occasionally observed in both MC (9.1%, 5/55 cases) and conventional adenocarcinoma (13.4%, 16/119 cases).
  • Although MLH-1 and CDX2 expression tended to be lower in conventional adenocarcinoma, none of the immunohistochemical results was significantly different between 2 groups.
  • Recognition of MC component is important as MC appeared to be an aggressive variant of colonic adenocarcinoma and presented at a higher stage, with frequent lymphovascular invasion, LN metastasis, and distant metastasis, compared with conventional adenocarcinoma.
  • The proportion of MC component did not impact the prognosis, and the immunoprofiles of MC were not significantly different from those of conventional adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / pathology. Colorectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16784979.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Hori Y, Uechi M, Kanakubo K, Sano T, Oyamada T: Canine ovarian serous papillary adenocarcinoma with neoplastic hypercalcemia. J Vet Med Sci; 2006 Sep;68(9):979-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Canine ovarian serous papillary adenocarcinoma with neoplastic hypercalcemia.
  • Exploratory laparotomy revealed an ovoid mass within the right ovary.
  • The right ovarian mass was diagnosed as a serous papillary adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17019069.001).
  • [ISSN] 0916-7250
  • [Journal-full-title] The Journal of veterinary medical science
  • [ISO-abbreviation] J. Vet. Med. Sci.
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


92. Ghossain MA, Chucrallah A, Kanso H, Aoun NJ, Abboud J: Multilocular adenomatoid tumor of the ovary: ultrasonographic findings. J Clin Ultrasound; 2005 Jun;33(5):233-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multilocular adenomatoid tumor of the ovary: ultrasonographic findings.
  • We report the sonographic findings of a rare benign ovarian tumor in a 69-year-old woman.
  • Transvaginal ultrasonography showed a cystic multilocular lesion with a vascularized central solid portion of the left ovary.
  • Adenomatoid tumors are benign lesions of mesothelial origin, usually solid in nature and rarely located in the ovaries. (c) 2005 Wiley Periodicals, Inc.
  • [MeSH-major] Adenomatoid Tumor / ultrasonography. Ovarian Neoplasms / ultrasonography
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / surgery. Aged. Colonic Neoplasms / diagnosis. Colonic Neoplasms / surgery. Female. Humans. Neoplasms, Multiple Primary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley Periodicals, Inc. J Clin Ultrasound 33:233-236, 2005.
  • (PMID = 16047378.001).
  • [ISSN] 0091-2751
  • [Journal-full-title] Journal of clinical ultrasound : JCU
  • [ISO-abbreviation] J Clin Ultrasound
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Stewart CJ, Brennan BA, Hammond IG, Leung YC, McCartney AJ, Ruba S: Intraoperative assessment of clear cell carcinoma of the ovary. Int J Gynecol Pathol; 2008 Oct;27(4):475-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative assessment of clear cell carcinoma of the ovary.
  • Frozen section is a reliable technique in gynecologic pathology and is widely used to guide intraoperative management in patients presenting with ovarian masses.
  • However, there are limited data regarding the diagnostic accuracy of frozen section in specific subtypes of ovarian neoplasia.
  • Difficulties in distinguishing primary ovarian carcinoma from tumors metastatic to the ovary occurred in a minority of cases of all histologic subtypes, but was slightly more frequent in CCC.
  • Review of the frozen-section slides from the CCC with discrepant intraoperative diagnoses showed features suggestive or indicative of the correct diagnosis in 7 (39%) of 18 cases.
  • [MeSH-major] Adenocarcinoma, Clear Cell / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18753976.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Uddin Z, Yaqoob N, Kayani N, Hasan SH: Clear cell carcinoma of ovary with associated mucinous cystadenoma and endometriosis. J Pak Med Assoc; 2007 Jul;57(7):373-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell carcinoma of ovary with associated mucinous cystadenoma and endometriosis.
  • A 45 year old woman presented with right sided ovarian mass with multiple omental deposits and liver metastases.
  • The right ovary was enlarged and showed a partly cystic partly solid cut surface.
  • [MeSH-major] Adenocarcinoma, Clear Cell / etiology. Cystadenoma, Mucinous / complications. Endometriosis / complications. Ovarian Neoplasms / etiology

  • Genetic Alliance. consumer health - Endometriosis.
  • MedlinePlus Health Information. consumer health - Endometriosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17867264.001).
  • [ISSN] 0030-9982
  • [Journal-full-title] JPMA. The Journal of the Pakistan Medical Association
  • [ISO-abbreviation] J Pak Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


95. Oishi T, Itamochi H, Kigawa J, Kanamori Y, Shimada M, Takahashi M, Shimogai R, Kawaguchi W, Sato S, Terakawa N: Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary. Int J Gynecol Cancer; 2007 Sep-Oct;17(5):1040-6
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
  • Our previous findings suggested that lower cell proliferation of clear cell carcinoma (CCC) of the ovary may contribute to its resistance to chemotherapy.
  • Complementary DNA microarray analysis revealed that the gene expression level of galectin-3 of CCC cell lines (KK, RMG-I, HAC-2) was over threefold higher than that of ovarian serous adenocarcinoma (SAC) cell lines (HRA, KF).
  • [MeSH-major] Adenocarcinoma, Clear Cell / metabolism. Drug Resistance, Neoplasm / genetics. Galectin 3 / physiology. Ovarian Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17433067.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Galectin 3; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


96. Schmeler KM, Tao X, Frumovitz M, Deavers MT, Sun CC, Sood AK, Brown J, Gershenson DM, Ramirez PT: Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary. Obstet Gynecol; 2010 Aug;116(2 Pt 1):269-73
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of lymph node metastasis in primary mucinous carcinoma of the ovary.
  • OBJECTIVE: To estimate the prevalence of lymph node involvement in women with primary mucinous ovarian carcinomas.
  • METHODS: A retrospective study was performed of patients with primary mucinous ovarian carcinomas evaluated at a single institution between 1985 and 2007.
  • Patients with tumors of low malignant potential and mucinous carcinomas metastatic to the ovary from other primary sites were excluded.
  • RESULTS: Patients with primary mucinous ovarian carcinomas were identified (n=107).
  • At time of surgery, 93 patients (87%) had tumors that grossly appeared to be confined to the ovary, and 14 patients (13%) had evidence of extraovarian disease.
  • Of the 93 patients with tumors that grossly appeared to be confined to the ovary at surgical exploration, 51 (55%) underwent lymphadenectomy (n=27 pelvic and paraaortic, n=19 pelvic only, n=5 paraaortic only).
  • CONCLUSION: There were no cases of isolated lymph node metastases among women with primary mucinous carcinoma grossly confined to the ovary, suggesting that routine lymphadenectomy may be omitted in these patients.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Lymph Nodes / pathology. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2001 Jan 20;357(9251):176-82 [11213094.001]
  • [Cites] J Am Coll Surg. 2003 Aug;197(2):198-205 [12892797.001]
  • [Cites] J Clin Oncol. 2004 Mar 15;22(6):1040-4 [15020606.001]
  • [Cites] Hum Pathol. 2004 Aug;35(8):918-33 [15297960.001]
  • [Cites] Gynecol Oncol. 2009 Jun;113(3):331-4 [19275957.001]
  • [Cites] Gynecol Oncol. 2005 May;97(2):436-41 [15863142.001]
  • [Cites] Gynecol Oncol. 2006 Dec;103(3):878-82 [16859736.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3621-7 [17704411.001]
  • [Cites] Gynecol Oncol. 2004 Sep;94(3):624-9 [15350350.001]
  • (PMID = 20664385.001).
  • [ISSN] 1873-233X
  • [Journal-full-title] Obstetrics and gynecology
  • [ISO-abbreviation] Obstet Gynecol
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS625325; NLM/ PMC4163054
  •  go-up   go-down


97. Feltmate CM, Lee KR, Johnson M, Schorge JO, Wong KK, Hao K, Welch WR, Bell DA, Berkowitz RS, Mok SC: Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas. Clin Cancer Res; 2005 Nov 1;11(21):7651-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Whole-genome allelotyping identified distinct loss-of-heterozygosity patterns in mucinous ovarian and appendiceal carcinomas.
  • PURPOSE: Mucinous adenocarcinoma of the ovary is one of the common histologic types of ovarian cancer.
  • In addition, the differential diagnosis of metastatic mucinous carcinomas to the ovaries, particularly those originating from the appendix, remains challenging.
  • The purpose of this study is to identify molecular biomarkers for mucinous ovarian adenocarcinoma and compare them with those of appendiceal origin.
  • EXPERIMENTAL DESIGN: Genome-wide loss-of-heterozygosity (LOH) analysis was done on DNA isolated from 28 microdissected primary mucinous ovarian carcinomas and five appendiceal adenocarcinomas.
  • Markers from high-loss regions were selected for further analysis on a total of 32 ovarian and 14 appendiceal cancers.
  • RESULTS: High levels of LOH rates (>40%) were detected on chromosome arms 9p, 17p, and 21q in mucinous ovarian carcinoma cases.
  • The frequency of allelic loss was similar between high-grade and low-grade mucinous ovarian carcinoma cases but was significantly higher in ovarian versus appendiceal cases.
  • In addition, LOH rates on five chromosomal loci were statistically different between ovarian and appendiceal carcinomas.
  • CONCLUSION: A high frequency of LOH can be found in mucinous ovarian adenocarcinomas independent of grade.
  • Despite histologic similarities between mucinous ovarian carcinomas and metastatic appendiceal carcinomas, they have distinct LOH profiles, which may be used for distinguishing the two diseases.
  • [MeSH-major] Adenocarcinoma, Mucinous / genetics. Appendiceal Neoplasms / genetics. Appendiceal Neoplasms / pathology. Carcinoma / genetics. Genome. Genotype. Heterozygote. Loss of Heterozygosity. Ovarian Neoplasms / genetics. Ovarian Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278384.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA165009; United States / NCRR NIH HHS / RR / RR33CA103595
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


98. Shameem M, Akhtar J, Baneen U, Bhargava R, Ahmed Z, Sharma P, Khan NA, Hassan MJ: Primary peritoneal adenocarcinoma causes pleural effusion. N Am J Med Sci; 2010 Jun;2(6):281-4

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary peritoneal adenocarcinoma causes pleural effusion.
  • CONTEXT: The most common malignancies associated with malignant pleural effusions are carcinomas of the breast, lung, gastrointestinal tract, ovary and lymphomas.
  • Primary peritoneal adenocarcinoma is a very rare cause of malignant pleural effusion.
  • A cytologic examination of pleural fluid revealed adenocarcinoma cells.
  • Her ovaries were normal and no other mass lesion was detected.
  • A histological examination of a peritoneal lesion was suggestive of adenocarcinoma.
  • CONCLUSIONS: The patient was diagnosed with a rare case of primary peritoneal adenocarcinoma with bilateral pleural effusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Obstet Gynecol. 1979 Nov;54(5):656-8 [503399.001]
  • [Cites] Int J Gynecol Pathol. 1994 Apr;13(2):120-6 [8005732.001]
  • [Cites] Gynecol Oncol. 1991 Jun;41(3):259-62 [1714418.001]
  • [Cites] Gynecol Oncol. 1991 Mar;40(3):230-6 [2013445.001]
  • [Cites] Obstet Gynecol. 1990 Jan;75(1):75-8 [2296426.001]
  • [Cites] Gynecol Oncol. 1988 Oct;31(2):315-20 [2458994.001]
  • [Cites] Cancer. 1989 Jul 1;64(1):110-5 [2731107.001]
  • [Cites] J Surg Oncol. 1998 Jul;68(3):173-8 [9701210.001]
  • [Cites] Gynecol Oncol. 1998 Nov;71(2):230-9 [9826465.001]
  • [Cites] Am J Obstet Gynecol. 1959 Jan;77(1):197-200 [13606191.001]
  • [Cites] Eur J Gynaecol Oncol. 1988;9(6):474-8 [3234425.001]
  • [Cites] Arch Pathol Lab Med. 1995 Nov;119(11):1044-9 [7487405.001]
  • [Cites] Gynecol Oncol. 1993 Nov;51(2):171-4 [8276289.001]
  • [Cites] Gynecol Oncol. 1993 Sep;50(3):347-51 [8406199.001]
  • [Cites] Int J Gynecol Pathol. 1995 Oct;14(4):310-8 [8598333.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):160-3 [9234939.001]
  • [Cites] Gynecol Oncol. 1997 Nov;67(2):141-6 [9367697.001]
  • [Cites] Histopathology. 2005 Sep;47(3):231-47 [16115224.001]
  • [Cites] Eur J Gynaecol Oncol. 2006;27(2):197-9 [16620072.001]
  • [Cites] Gynecol Oncol. 2007 Jun;105(3):762-8 [17383715.001]
  • [Cites] Ann Oncol. 2001 Apr;12(4):563-7 [11398893.001]
  • [Cites] Int J Gynecol Cancer. 2003 Nov-Dec;13(6):764-70 [14675312.001]
  • [Cites] Obstet Gynecol. 1989 May;73(5 Pt 1):786-92 [2704507.001]
  • [Cites] Hum Pathol. 1989 May;20(5):426-36 [2707793.001]
  • [Cites] Histopathology. 1988 May;12(5):527-32 [3397046.001]
  • [Cites] Int J Gynecol Pathol. 1985;4(1):11-23 [3880151.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):905-9 [4016683.001]
  • [Cites] Lancet. 1982 Oct 9;2(8302):795-7 [6126666.001]
  • [Cites] Hum Pathol. 1990 Jan;21(1):99-110 [1688545.001]
  • (PMID = 22574304.001).
  • [ISSN] 1947-2714
  • [Journal-full-title] North American journal of medical sciences
  • [ISO-abbreviation] N Am J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC3347636
  • [Keywords] NOTNLM ; Malignant pleural effusion / primary peritoneal adenocarcinoma
  •  go-up   go-down


99. Bose CK, Bose B, Basu A, Basu S: Liposomal doxorubicin in suspected ovarian carcinoma patient with very low creatinine clearance test value. Medscape J Med; 2008;10(3):53
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liposomal doxorubicin in suspected ovarian carcinoma patient with very low creatinine clearance test value.
  • A 74-year-old woman presented with moderate ascites with diagnostic features of adenocarcinoma of the ovary.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / urine. Creatinine / urine. Doxorubicin / therapeutic use. Kidney Diseases / urine. Ovarian Neoplasms / drug therapy. Ovarian Neoplasms / urine

  • MedlinePlus Health Information. consumer health - Creatinine.
  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Expert Opin Pharmacother. 2006 Aug;7(11):1469-74 [16859430.001]
  • [Cites] Gynecol Oncol. 2007 Aug;106(2):375-80 [17512575.001]
  • [Cites] Tumori. 2006 Jul-Aug;92(4):364-5 [17036534.001]
  • (PMID = 18449344.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 80168379AG / Doxorubicin; AYI8EX34EU / Creatinine
  • [Other-IDs] NLM/ PMC2329759
  •  go-up   go-down


100. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, Dodson WC: The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol; 2007 Apr;196(4):402.e1-10; discussion 402.e10-1
Hazardous Substances Data Bank. ROSIGLITAZONE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome.
  • OBJECTIVE: To examine the effects of metformin and rosiglitazone, alone and in combination, on endometrial histology and ovarian steroid production.
  • STUDY DESIGN: Randomized open-label study of metformin and rosiglitazone in 16 women with polycystic ovary syndrome (PCOS) performed at a single academic health center.
  • RESULTS: Abnormal endometrial histology was found in 3 subjects at baseline, including 1 case of adenocarcinoma of the endometrium in an asymptomatic subject, who was excluded from further study.
  • [MeSH-major] Endometrium / pathology. Metformin / therapeutic use. Ovary / pathology. Polycystic Ovary Syndrome / drug therapy. Thiazolidinediones / therapeutic use

  • MedlinePlus Health Information. consumer health - Polycystic Ovary Syndrome.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METFORMIN HYDROCHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403436.001).
  • [ISSN] 1097-6868
  • [Journal-full-title] American journal of obstetrics and gynecology
  • [ISO-abbreviation] Am. J. Obstet. Gynecol.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / C06 RR016499; United States / NICHD NIH HHS / HD / K24 HD001476; United States / NCRR NIH HHS / RR / M01 RR010732
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Thiazolidinediones; 05V02F2KDG / rosiglitazone; 9100L32L2N / Metformin
  •  go-up   go-down






Advertisement